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Summary 
Hepatitis B virus (HBV) can infect only a few cell types including primary Tupaia 
hepatocytes (PTH) which were used in this work. The aim of the study was to characterize 
the early steps of HBV infection using pharmacological inhibitors and confocal microscopy. 
The distinction between endocytosis in general and direct fusion with the plasma 
membrane was made by using hypertonic sucrose concentrations. The fusion of Sendai 
virus (SeV) with the plasma membrane and its infectivity was not affected, whereas the 
infection of control viruses known to be taken up via endocytosis, e.g. Semliki Forest virus 
(SFV) and Simian virus 40 (SV40), was impeded. The HBV infection was inhibited in a 
dose-dependent manner, suggesting an endocytic uptake. The dynamin inhibitor Dynasore 
completely inhibited the entry of SFV (clathrin-mediated endocytosis) and SV40 (caveolin-
mediated endocytosis), but had no effect on HBV suggesting a dynamin-independent 
internalization. Furthermore, the inhibitor of macropinocytosis EIPA did not impair HBV 
infection. HBV was also not able to stimulate the macropinocytic activity of PTH. Also 
phagocytosis could be ruled out as an entry mechanism. The actin inhibitors Jasplakinolide 
(actin-stabilisation) or Cytochalasin D (actin-depolymerisation) resulted in a partial 
inhibition of the early steps of HBV infection. The intracellular transport of HBV could be 
constrained by utilization of Nocodazole, an inhibitor of microtubule-polymerisation. HBV 
does not require an acidic pH within the endosomal compartments for the initiation of a 
productive infection cycle and therefore differs from many other viruses that are 
internalized via endocytosis (e.g. SFV, which was tested as control virus) and also from the 
related hepatitis B virus of the duck. No parallels to the retrograde pathway of SV40 were 
observed, since the HBV infection showed no sensitivity towards inhibitors of specific 
intracellular transport mechanisms (Brefeldin A), ER protein folding and quality factors 
(MG-132) and the translocation process to the cytosol (Thapsigargin). Together with 
previous data it can be concluded that HBV is internalized via a not yet known, possibly 
virus-induced, endocytic uptake mechanism, which is clathrin-, caveolin-, lipid raft- and 
dynamin-independent and differs from the process of phagocytosis and macropinocytosis.
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Zusammenfassung 
Hepatitis B Virus (HBV) kann nur wenige Zelltypen infizieren, u.a. primäre Tupaia 
Hepatozyten (PTH), die hier eingesetzt wurden. Die frühen Schritte der HBV-Infektion sind 
noch unbekannt und sollten mithilfe von pharmakologischen Inhibitoren und konfokaler 
Mikroskopie charakterisiert werden. Die Unterscheidung zwischen allen Arten von 
Endozytosevorgängen und der direkten Fusion von Virushüllen mit der Plasmamembran 
erfolgte durch Behandlung mit hyperosmolaren Sucrosekonzentrationen. Die Fusion des 
Sendai Virus (SeV) mit der Plasmamembran und dessen Infektiosität wurden dadurch nicht 
beeinflusst, während die Infektion endozytisch aufgenommener Kontrollviren, z.B. des 
Semliki Forest Virus (SFV) sowie des Simian Virus 40 (SV40), unterbunden werden konnte. 
Auch die Infektion mit HBV wurde dosis-abhängig inhibiert, was auf eine endozytische 
Aufnahme schließen lässt. Der Dynamin-Inhibitor Dynasore konnte die Eintrittsprozesse 
von SFV (Clathrin-vermittelte Endozytose) und SV40 (Caveolin-vermittelte Endozytose) 
vollständig unterbinden, hatte jedoch keinen Einfluss auf die HBV-Infektion, was auf einen 
Dynamin-unabhängigen Internalisierungsprozess hindeutet. Auch der Inhibitor der 
Makropinozytose EIPA inhibierte die HBV-Aufnahme nicht. Außerdem stimulierte HBV 
nicht die Makropinozytose in PTH. Phagozytose konnte als Eintrittsmechanismus ebenfalls 
ausgeschlossen werden. Die Aktin-Inhibitoren Jasplakinolide (Aktin-Stabilisierung) bzw. 
Cytochalasin D (Aktin-Depolymerisierung) führten zu einer partiellen Inhibition der frühen 
Schritte der HBV Infektion. Der intrazelluläre Transport von HBV konnte durch Nocodazol, 
einem Inhibitor der Mikrotubuli-Polymerisation, behindert werden. HBV benötigt für die 
Infektion keinen sauren pH innerhalb der endosomalen Kompartimente und unterscheidet 
sich damit von vielen anderen endozytisch aufgenommenen Viren (u.a. dem Kontrollvirus 
SFV) und auch vom verwandten Hepatitis B Virus der Ente. Ein retrograder Aufnahmeweg 
wie bei SV40 liegt bei HBV nicht vor, da entsprechende Inhibitoren bestimmter 
intrazellulärer Transportprozesse (Brefeldin A), ER-Proteinfaltungs-und Qualitätsfaktoren 
(MG-132) sowie des Translokationsprozesses ins Zytosol (Thapsigargin) wirkungslos 
blieben. Zusammen mit früheren Daten kann postuliert werden, dass HBV über einen 
bislang unbekannten, möglicherweise vom Virus selbst-induzierten, endozytischen 
Aufnahmemechanismus internalisiert wird, welcher Clathrin-, Caveolin-, lipid raft- und 
Dynamin-unabhängig ist und sich vom Prozess der Phagozytose und Makropinozytose 
unterscheidet.  
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1. Introduction 
1.1 Endocytosis 
Endocytosis is an internalization process that occurs at the cell surface and has vital 
physiological roles: Invagination of plasma membrane (PM) regions is used to regulate the 
protein and lipid content of the cellular surface (maintenance of homeostasis) and thereby 
controls cell-environmental interactions. Nutrient uptake and modulation of surface 
receptor signaling are also important roles of endocytic processes and indispensable for cell 
and tissue function (Doherty and Lundmark 2009; Kumari et al. 2010). It is also required 
for cell adhesion, cell morphology changes, such as establishment of cellular asymmetry or 
migration, antigen presentation and mitosis (Doherty and Lundmark 2009; Doherty and 
McMahon 2009). There is no evidence for an endocytic system in prokaryotes whereas a 
variety of different processes is found in eukaryotic organisms including protozoans, for 
example Trypanosoma, Paramecium, amoebae, certain fungi etc. as well as metazoans, 
such as plants, invertebrates and vertebrates. Obviously, the different kingdoms have 
evolved specialized endocytic processes based on environmental adaptations and molecular 
divergence (Allen et al. 2003; Dacks and Field 2007; Kumari et al. 2010). Over the years, a 
diversity of endocytic pathways in eukaryotes has been discovered mainly by studies in 
mammalian cells (Fig. 1).  
 
Figure 1: Entry pathways into cells. EE: early endosome, ER: endoplasmic reticulum, MTOC: microtubule 
organizing centre; L: lysosome; LE: late endosome, RE: recycling endosome; TGN: trans Golgi network. CLIC: 
clathrin-independent carriers; GEEC: GPI-AP enriched ensosomal compartment.    
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1.1.1 Entry of pathogens 
Viruses are obligatory intracellular parasites and characterized by an extremely simple 
structure. They lack any metabolic or motile activities therefore being strictly dependent on 
hosts. In order to invade and infect their host cells, viruses first bind to cell surface 
structures which can be proteins, lipids or carbohydrates. Some of them merely serve as 
attachment factors which help to concentrate viruses on the cellular surface. Unlike such 
relatively unspecific and reversible binding to e.g. carbohydrate structures, binding to high-
affinity receptors is usually specific and actively promotes viral entry. In addition to this, 
many viruses use the cellular signaling pathways to make their presence on the cell surface 
known. Those signaling activities induce changes in the host cell thereby setting-up specific 
endocytic mechanisms (Marsh and Helenius 2006). Cells offer a variety of endocytic and 
trafficking mechanisms that are hijacked by viruses to cross membranes or other barriers 
and deliver their genomes to their replication site within the cytoplasm or the nucleus    
(Fig. 1). Some viruses can penetrate into the cytosol directly through the PM (e.g. Herpes 
simplex virus 1, HSV-1, or Sendai virus, SeV) but most depend on endocytic uptake. One 
advantage of endocytosis is that endocytic vesicles ferry their “virus-cargo” from the 
periphery of the cell through the crowded cytoplasm to a more perinuclear area, bypassing 
barriers, such as the actin cortex, and exploiting molecular motors recruited to the vesicles 
(Dohner and Sodeik 2005; Mercer et al. 2010). A further advantage of endocytosis whereof 
viruses benefit, is the condition within maturing endosomes: The pH decrease, the presence 
of specific proteases and changes in the redox environment provide cues that trigger 
penetration and uncoating (Smith and Helenius 2004; Mercer et al. 2010). Finally, viruses 
that penetrate from intracellular organelles avoid leaving viral proteins exposed on the PM 
therefore causing a delay in immune detection (Smith and Helenius 2004). A risk that 
viruses must accept when using endocytosis, is the possible delivery to lysosomes which 
means degradation and a dead-end for most pathogens. That is the reason why viruses have 
adjusted the threshold pH for activation to match that of early or late endosomes (Smith 
and Helenius 2004). By utilizing the internalization and trafficking machineries of the host 
cell, i.e. pleiomorphic endosomal compartments that fuse with one another and thereby 
promoting trafficking, viruses find the correct replication site for progress of the infectious 
life cycle (Sieczkarski and Whittaker 2002).   
 
1.2 Pathways of entry into cells 
Classification of endocytic mechanisms is rather complicated since many different factors 
are involved and may be required in more than one route (Fig. 1). In the following, the 
pathways are classified based on their dependence on the GTPase dynamin. Dynamin is an 
essential component of vesicle formation during endocytosis, synaptic vesicle recycling and 
perhaps vesicle trafficking in and out of the Golgi (Hinshaw 2000). To date, three dynamin 
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genes have been identified in mammalian cells, each expressing at least four different 
alternatively spliced forms. Dynamin-1 is found specifically in neuronal cells, Dynamin-2 is 
ubiquitously expressed whereas Dynamin-3 is expressed predominantly in testes but also 
appears in lung and brain (Hinshaw 2000). There is evidence that the different isoforms 
and splice variants function at distinct locations within the cell (Cao et al. 1998; Hinshaw 
2000). Dynamin self-assembles into higher-ordered structures resembling rings or spirals. 
This dynamic oligomerization leads to constriction of invaginated membrane areas and 
budding of a vesicle. However, its exact mechanism of action is still controversially 
discussed (Mettlen et al. 2009). 
 
1.2.1 Dynamin-dependent endocytosis 
1.2.1.1 Clathrin-mediated endocytosis 
Clathrin-mediated endocytosis (CME) is the best-studied endocytic pathway. It involves 
clathrin, which shapes cage-like membrane invaginations (clathrin coated pits, CCPs) on 
the cytoplasmic face of the PM that pinch off by the action of dynamin and become free 
clathrin-coated vesicles (CCVs) (Pearse 1976; Marsh and McMahon 1999). Clathrin 
functions as a trimer of heterodimers, the so-called triskelion, which assembles into a 
lattice-like structure forming vesicles of different sizes ranging from 100-200 nm in 
diameter (Pearse 1976; Kumari et al. 2010). Additionally, interaction of clathrin with 
several accessory proteins like adaptor proteins (e.g. AP-2 or AP-180), amphiphysin, Epsin, 
Eps15 etc. is required for scaffold formation, local membrane deformation and generation 
of CCPs/CCVs (Kirchhausen 1999; Marsh and McMahon 1999). CME is a constitutive 
process responsible for the internalization of PM receptors and also provides a continuous 
rapid and efficient route for virus entry (Benmerah and Lamaze 2007; Hansen and Nichols 
2009). It transports incoming viruses within minutes to early or late endosomes where the 
acidic pH leads to conformational changes in the particles and triggers fusion of the viral 
and the endosomal membranes (Marsh and Helenius 2006). Several viruses use this 
pathway for internalization e.g. Semliki Forest Virus (SFV), Hepatitis C Virus (HCV), SARS 
Coronavirus, Vesicular Stomatitis Virus (VSV) and many others (Helenius et al. 1980; Sun 
et al. 2005; Marsh and Helenius 2006; Inoue et al. 2007). 
 
1.2.1.2 Caveolin-mediated uptake 
Until the early 1990s there was controversy whether clathrin-independent (CI) endocytosis 
exists at all (Hansen and Nichols 2009). Studies on the uptake of different types of 
endogenous and exogenous cargoes showed that pharmaceutical perturbation of CME did 
not block all kinds of endocytosis (Doherty and McMahon 2009; Hansen and Nichols 
2009). Probably the best-characterized dynamin-dependent CI pathway is the caveolin-
mediated endocytosis (Mayor and Pagano 2007). It is often equated with lipid rafts which is 
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not entirely true, since caveolae present only one subset of lipid rafts (Simons and Toomre 
2000). Therefore here, the term “caveolae” is used for invaginations of the PM containing 
caveolin. Caveolae were already recognized in the 1950s by electron microscopy (EM) due to 
their characteristic flask-shaped morphology (Palade 1953). They are 50-80 nm in diameter 
and are enriched in caveolins, sphingolipids and cholesterol (Mayor and Pagano 2007).  
There are three mammalian caveolin proteins: Caveolin-1 (cav-1) is co-expressed with 
caveolin-2 (cav-2) in cells with abundant caveolae, such as endothelial cells, adipocytes and 
fibroblasts, caveolin-3 (cav-3) is muscle-specific (Ikonen et al. 2004; Doherty and 
McMahon 2009). Caveolae have been implicated in endocytosis, transcytosis and signal 
transduction but since they are abundant in some cell types (see above) but undetectable in 
others, e.g. lymphocytes, neurons and hepatocytes, their general cellular function remains 
unclear (Parton and Richards 2003). Caveolae are relatively stable and immobile in the PM 
and bud only infrequently suggesting no involvement in constitutive endocytic trafficking 
(Thomsen et al. 2002). However, it has been shown that dynamin is recruited to caveolae 
and some pinch off the membrane (Oh et al. 1998; Kirkham et al. 2005). Accordingly, some 
viruses, certain bacteria as well as bacterial toxins make use of this uptake route, e.g. Simian 
Virus 40 (SV40), Echo 1 Virus, papilloma viruses, certain E.coli strains, Cholera Toxin B 
(CtxB) etc. (Oh et al. 1998; Parton and Richards 2003; Smith and Helenius 2004; Kirkham 
et al. 2005; Marsh and Helenius 2006). The internalized cargoes are either routed to acidic 
early endosomes or to pH-neutral caveosomes from where they are further transported to 
reach their penetration or replication site (Marsh and Helenius 2006; Mayor and Pagano 
2007). 
 
1.2.1.3 Other pathways 
Another dynamin-dependent CI mechanism is responsible for uptake of the β-chain of the 
interleukin-2 receptor (IL-2R-β), for internalization of other receptors in immune cells and 
fibroblasts and is possibly used by Rotavirus (Mayor and Pagano 2007; Doherty and 
McMahon 2009; Mercer et al. 2010). The pathway is dependent on the small G-proteins 
RhoA and Rac1 (Doherty and McMahon 2009). Particular proteins coating the endocytic 
vesicles are currently not known and their exact morphology is still unclear (Doherty and 
McMahon 2009). 
 
1.2.2 Dynamin-independent endocytosis 
1.2.2.1 Phagocytosis 
Phagocytosis and macropinocytosis (see following chapter 1.2.2.2) belong to a separate class 
of endocytic processes that involve the uptake of large membrane patches of >1 µm and 
generation of large, uncoated vacuoles with a diameter of 0.5-10 µm (Mayor and Pagano 
2007; Hansen and Nichols 2009; Mercer and Helenius 2009). Phagocytosis is an endocytic 
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mechanism used by lower organisms for nutrient acquisition (Aderem and Underhill 1999), 
in metazoa it occurs in specialized cell types including macrophages (e.g. the Kupffer cells of 
the liver), monocytes and neutrophils and displays a major mechanism for the degradation 
of large particles, like apoptotic cell debris and pathogens (Aderem and Underhill 1999; 
Conner and Schmid 2003). In order to discriminate between self and non-self particles, 
cells have evolved different receptors and types of phagocytic processes (Aderem and 
Underhill 1999). Internalization by phagocytosis is specific and particle-driven. The 
attachment of the particle to the PM not only triggers the mechanism but also guides the 
formation of local actin-protrusions that, in some cases even “zipper up”, to tightly enclose 
the receptor-coated particle (Anderem and Underhill 1999; Mercer et al. 2010). After 
internalization, the phagosome undergoes maturation by several fusion and fission events 
with other endosomal compartments. Thereby gradual acidification takes place which 
finally leads to particle degradation (Aderem and Underhill 1999). Despite the efficiency of 
the innate immune system in detecting and destroying pathogens, certain bacteria, such as 
Legionella or Shigella, have developed mechanisms to escape degradation and some even 
persist and replicate inside phagosomes (Kinchen and Ravichandran 2008). Also some 
large viruses use this pathway to infect host cells as shown with HSV-1 and Mimivirus 
(Clement et al. 2006; Ghigo et al. 2008).   
 
1.2.2.2 Macropinocytosis 
Macropinocytosis has diverse functions ranging from nutrient uptake in amoeba (Koivusalo 
et al. 2010) to an involvement in cell migration and antigen presentation in some cell types 
(Ghigo 2010). An important feature of this mechanism is the requirement for extensive 
reorganization of the actin cytoskeleton (Schelhaas 2010). This rearrangement frequently 
involves PM protrusions ( e.g. lamelipodia, filopodia or blebs) that subsequently either fuse 
with themselves or back with the PM, resulting in the formation of large, heterogeneous 
vesicles known as macropinosomes (Sieczkarski and Whittaker 2002; Doherty and 
McMahon 2009; Mercer et al. 2010). The definite fate of those vesicles is cell type-
dependent, but it is known that they can intersect with other organelles of the 
endolysosomal system during their maturation process, offering possible routes for the 
entry of diverse pathogens (Sieczkarski and Whittaker 2002; Kerr and Teasdale 2009; 
Ghigo 2010). In contrast to phagocytosis, macropinocytosis is considered as a nonspecific 
internalization process of large amounts of fluids and solutes that does not rely on ligand 
binding to a specific receptor (Sieczkarski and Whittaker 2002). In certain cell types, such 
as dendritic cells, it is a constitutive process and a major route of entry that does not require 
stimulation (Sieczkarski and Whittaker 2002; Mercer and Helenius 2009; Kumari et al. 
2010). However, in most situations, it is a transient mechanism since macropinosomes are 
usually not found in resting, unstimulated cells but formed upon growth-factor induced 
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stimulation of cells (Nichols and Lippincott-Schwartz 2001; Sieczkarski and Whittaker 
2002). A variety of particles can induce “membrane ruffling” thus promoting their 
incidental internalization together with fluid into macropinosomes (Mercer and Helenius 
2009). These are for example bacteria like Shigella and Salmonella (Kumari et al. 2010) 
and also viruses from different families use macropinocytosis for entry, such as Adenovirus 
type 3 (Ad3), HIV-1, HSV-1 and Vaccinia Virus (Kumari et al. 2010; Mercer et al. 2010).  
 
1.2.2.3 CLIC-GEEC 
Another constitutive dynamin-and clathrin-independent endocytic pathway that is used for 
the internalization of glycosyl phosphatidylinositol-anchored proteins (GPI-APs) is 
represented by a mechanism mediated by primary carriers called clathrin-independent 
carriers (CLICs) which fuse to tubular compartments called GPI-AP enriched endosomal 
compartments (GEECs) (Sabharanjak et al. 2002; Mayor and Pagano 2007). Beside the role 
in GPI-AP uptake, the CLIC/GEEC pathway is also responsible for endocytosis of large 
amounts of extracellular fluid, CtxB, the plant toxin ricin and Helicobacter pylori 
vacuolating toxin (VacA) (Kalia et al. 2006; Mayor and Pagano 2007; Kumari et al. 2010). 
Endocytosis through this route has been shown to be dependent on the activity of the small 
GTPases Cdc42 and Arf1 (Kumari and Mayor 2008). Recently, the first specific non-cargo 
marker of CLIC tubules has been identified: GRAF1 (GTPase regulator associated with focal 
adhesion kinase-1) localizes predominantly to pleiomorphic tubular structures which are 
~40 nm in diameter and is probably used to generate or stabilize membrane curvature 
(Kumari and Mayor 2008; Lundmark et al. 2008). Until now, no viruses have been shown 
to use this route as entry pathway but since it has been discovered just recently, further 
work will determine its biological functions and identify other exogenous cargoes. 
 
1.2.2.4 Other pathways 
There is growing evidence that in addition to the established internalization mechanisms 
(see above) more pathways exist which exhibit differences among each other. They lack 
detectable coats as seen by EM and are independent of clathrin and caveolin (Mercer et al. 
2010). Examples are the ADP-ribosylation factor 6 (Arf6)-dependent pathway, the Flotilin-
associated route and the endocytic mechanism via tetraspanin-enriched microdomains 
(TEMs).  
The Arf6-pathway is important for the uptake of MHC-1 (major histocompatibility complex 
1), IL-2R-α as well as β1-integrin and it resembles the CLIC/GEEC route since here also 
tubular structures appear and certain GPI-APs are taken up (Sandvig et al. 2008). However, 
it is likely that these processes are distinct modes of trafficking since inhibition of GRAF1 
does not affect MHC-1 internalization (Sandvig et al. 2008; Kumari et al. 2010).  
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Flotilin proteins 1 and 2 have a similar topology to cav-1 but are not enriched in caveolae 
(Doherty and McMahon 2009). They are found oligomerized in distinct microdomains 
resembling caveolae and can be detected in cav-1-deficient cells (Doherty and McMahon 
2009; Hansen and Nichols 2009). Flotilin 1 is necessary for CD59 uptake and a portion of 
CtxB internalization. Furthermore, it is needed for the uptake of cell surface proteoglycans 
(Doherty and McMahon 2009; Hansen and Nichols 2009). Until now, no virus has been 
associated to enter through the Arf6-or flotilin-dependent pathway. 
Another form of endocytosis is supported by TEMs. It does not rely on caveolins, flotilins or 
lipid rafts and is distinct from macropinocytosis and phagocytosis (Mercer et al. 2010). 
Infectious entry of Human Papilloma Virus 16 (HPV-16), originally proposed to occur via 
CME, has recently been shown to involve TEMs (Spoden et al. 2008).  
 
1.2.3 pH dependence of viral infection 
The intracellular space of eukaryotic cells is compartmentalized into organelles with 
different properties thus providing diverse local environments for specific functions. A 
distinctive feature of organelles is e.g. their luminal pH-value which ranges from neutral in 
the ER to acidic in endosomes or lysosomes. Acidic pH is important for a number of events 
including protein-processing and degradation, membrane trafficking and dissociation of 
receptor-ligand complexes after internalization (Jefferies et al. 2008; Lafourcade et al. 
2008; Sun-Wada and Wada 2010). Furthermore, the acidic pH within endosomes is also 
crucial for a productive infection of various viruses, such as SFV, Sindbis and Influenza, and 
provides cues that trigger penetration and uncoating (Helenius et al. 1980; Glomb-
Reinmund and Kielian 1998; Smith and Helenius 2004). 
 
1.2.4 Role of the cytoskeleton for endocytic pathways 
The cytoskeleton is essential for the survival of most cells: filaments provide internal 
mechanical support, force to drive cell motion and tracks for movement of organelles and 
macromolecules throughout the cytoplasm (Pollard and Cooper 2009). Furthermore, there 
is evidence that especially actin plays an important role during endocytosis (Smythe and 
Ayscough 2006; Mercer et al. 2010). Processes like macropinocytosis and phagocytosis 
involve dramatic membrane remodeling and strictly depend on the formation of actin 
ruffles for the internalization of extracellular components or particles (Doherty and 
McMahon 2009). In pinocytic pathways, the cortical actin constitutes a submembranous 
barrier that is transiently depolymerized upon virus binding which allows endocytosis to 
proceed (Marsh and Helenius 2006; Doherty and McMahon 2009). The dynamic 
reassembly of actin might be then required to facilitate vesicle formation and its fission as 
well as providing a track for subsequent trafficking over short distances (Mayor and Pagano 
2007; Doherty and McMahon 2009; Pollard and Cooper 2009). In eukaryotic cells, many 
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different accessory proteins have been described to be concerned with the actin machinery 
and a number of those are proteins involved in endocytic processes (Fujimoto et al. 2000; 
Doherty and McMahon 2008; Polard and Cooper 2009). Although actin is often found 
associated with some endocytic events, it does not seem to be essential for all pathways 
since its contribution varies depending on the different cell types or, within the same cell 
type, under different conditions (Fujimoto et al. 2000; Doherty and McMahon 2008). 
 
1.3 Hepatitis B Virus (HBV) 
1.3.1 Taxonomy 
HBV belongs to the Hepadnaviridae, a family of hepatotropic and highly species-specific 
DNA viruses that is divided into two genera: the Orthohepadnavirus of mammals and the 
Avihepadnavirus of birds. Orthohepadnaviruses were discovered in humans (HBV) (Dane 
et al. 1970), Old World primates such as gorillas (GoHBV) (Grethe et al. 2000), orang-utans 
(OuHBV) (Warren et al. 1999), chimpanzees (ChHBV) (Vaudin et al. 1988) and gibbons 
(GiHBV) (Norder et al. 1996) as well as in the woolly monkey (WMHBV), a New World 
primate (Lanford et al. 1998). Furthermore, several rodents of the Sciuridae (squirrels) 
serve as hosts, e.g. the North American Woodchuck (WHV) (Summers et al. 1978), the 
California ground squirrel (GSHV) (Marion et al. 1980) and the Arctic Ground squirrel 
(ASHV) (Testut et al. 1996). Avihepadnaviruses are found in various bird species, e.g. 
Peking ducks (DHBV) (Mason et al. 1980), herons (HHBV) (Sprengel et al. 1988), cranes 
(CHBV) (Prassolov et al. 2003). HBV is divided into nine genotypes, A to I, based on >8% 
nucleotide variation over the entire genome (Norder et al. 2004; Yu et al. 2010). The 
various genotypes reflect a prevalent ethnical distribution (Bartholomeusz and Schaefer 
2004). 
 
1.3.2 Transmission and disease 
HBV is the causative agent of viral hepatitis type B, an inflammation of the liver which can 
take an acute or chronic course. Transmission of HBV occurs via blood or other body fluids 
(i.e. saliva, semen and vaginal fluid) by sexual contact, needle sharing between drug addicts 
etc. (horizontal transfer). Due to extremely high virus titres of up to ≥ 1010/ml in the blood 
of viraemic carriers, very small amounts of serum (1 nl) can be sufficient for infection 
(Gerlich 2002). In the majority of chronic cases transmission occurs vertically from 
mothers to their neonates perinatally. Infections via blood transfusions, once a common 
route of transmission, are negligible in developed countries, since the development of 
advanced diagnostic tests, broader screening for infection as well as improved production 
methods (e.g. for virus-inactivated plasma derivates) became standard condition (Lavanchy 
2004).  
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Hepatitis B is a potentially life-shortening liver infection and a major global health problem. 
According to estimates of the WHO (World Health Organization) two billion people 
worldwide have been infected with HBV, approx. 370 million are chronic carriers and about 
1 million people die each year due to the long term sequelae of the disease. The prevalence 
of HBV infection varies greatly throughout the world. In western countries, like Europe and 
North America less than 1% of the population is chronically infected whereas in high 
endemic countries, like Africa, China and other parts of Asia, 8-10% of the adult population 
become infected during early childhood (Lavanchy 2005). The course of infection is variable 
and depends on the infectious dose and fitness of the virus and is also regulated by age, 
gender and the state of health of the infected person. Wildtype HBV has no direct cytopathic 
effect, whereas variants of the virus may have an impact on pathogenesis. There is growing 
consensus that especially the virus-specific T-cell response is the key determinant 
influencing the pathogenesis of HBV infection (Chisari and Ferrari 1995; Chisari 1997; 
Baumert et al. 2007). In about 90% of healthy adults low dose-infections lead to a minor 
viral replication which is eliminated later and results in immunity. Infections with a higher 
dose predominantly lead to an acute hepatitis B, characterized by general malaise, extreme 
fatigue, nausea and sometimes jaundice (yellowing of the skin and eyes). The symptoms 
may last several weeks before the patient recovers and immunity is induced. The most 
severe form of an acute illness is the fulminant hepatitis B which proceeds in <1% of all 
cases. It leads to hepatic encephalopathy, failure of the coagulation system and, if left 
untreated, in 70% of cases to death (Ganem and Prince 2004). The likelihood that a chronic 
hepatitis emerges from an acute infection depends on the age at which a person becomes 
infected. Neonates and young children are the most likely to develop a chronic infection. 
About 25% of adults who become chronically infected during early childhood, later die from 
the consequences which may be cirrhosis (scarring of the liver) or hepatocellular carcinoma 
(HCC). Cirrhosis and HCC-incidence has increased worldwide with HCC being the 5th most 
frequent cancer (Lavanchy 2005). 
 
1.3.3 Prevention and therapy 
HBV infection is a preventable disease. A safe and effective vaccine is available since 1982 
and is 95% effective in preventing the disease and its consequences (Lavanchy 2004). 
Currently, SHBs is the only component of the widely used vaccines. Antibodies against this 
region are neutralizing in vitro and in vivo and protect infection in most cases, but may fail 
to protect against naturally occurring escape-mutants (Carman et al. 1993) or mutants 
selected during antiviral therapy (Kamili et al. 2009). To counteract this problem, the 
preS1-domain, essential for virus attachment, ought to be included into the vaccine (Bremer 
et al. in press).  
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Despite the existence of a vaccine, an estimated 370 million people are chronically infected 
worldwide implicating the consequences of cirrhosis and HCC. Antiviral treatment is used 
for preventing liver disease and development of HCC and suppression of virus replication. 
One option for treatment is interferon alpha (IFNα) which modulates the immune 
responses against HBV and has antiviral activity (Lavanchy 2004). However, it is associated 
with side effects such as flu-like symptoms (Tillmann 2007). The different available 
nucleos(t)ides analogues, e.g. Lamivudine, Adefovir, Entecavir and Tenofovir block the viral 
reverse transcriptase and thus formation of mature virus, offer the advantage of minimal 
side effects but lead to selection of HBV mutants and often result in development of 
resistance during therapy (Tillmann 2007). For this reason, antivirals that target other 
steps of the viral life cycle, e.g. attachment and entry, rcDNA to cccDNA conversion, 
assembly or budding, are under development. Myrcludex B is currently the only 
representative of a novel class of HBV entry inhibitors. It is an acylated peptide 
corresponding to the preS1-region of the large HBV surface protein and is known to block 
virus entry in vitro and in vivo and is currently developed as an antiviral approach (Glebe et 
al. 2005; Gripon et al. 2005; Petersen et al. 2008). 
 
1.3.4 Morphology 
The enveloped HBV has a diameter of 42-47 nm and is therefore one of the smallest animal 
viruses known (Dane et al. 1970) (Fig. 2). In electron microscopy the virions appear as 
characteristic double-shelled particles after negative staining (a). The virions contain a core 
particle which can be released from the lipid envelope by detergent (Almeida et al. 1971). 
Infected hepatocytes secrete virions and, in a huge excess, noninfectious subviral particles 
which consist of empty viral enveloped. They form 17-25 nm spheres and filamentous 
structures variable in length (Robinson 1977) (b). Both the virion and the subviral particles 
possess in their lipid envelope three different surface proteins: these are the L-(large), M-
(middle) and S-(small) hepatitis B surface (HBs) proteins which have a co-terminal carboxy 
terminus but differ in their N-terminal sequences (Heermann et al. 1984) and glycosylation 
pattern (Schmitt et al. 1999). The SHBs contains only the S-domain, the MHBs is formed by 
the S-and preS2-domain and finally the LHBs which consists of the S-, preS2-and preS1-
domain. The preS(1+2) domain of LHBs has a dual topology in the particles either lying 
within the lumen or being outwards exposed (Bruss et al. 1994; Lambert and Prange 2001). 
The HBV nucleocapsid (core particle, HBc) has a diameter of 32-36 nm and an icosahedral 
T3-or T4-symmetry made of 180 subunits (T3) or 240 subunits (T4) of the hepatitis B core 
antigen (HBcAg) (Crowther et al. 1994; Kenney et al. 1995; Dryden et al. 2006; Seitz et al. 
2007). The capsid encloses the HBV genome (Robinson 1974; Summers et al. 1975) with the 
viral polymerase covalently bound to the DNA (Gerlich and Robinson 1980). The 
polymerase is a multifunctional enzyme consisting of four subunits: priming domain, 
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reverse transcriptase domain, RNase H domain and a non-essential spacer domain 
(Bartenschlager and Schaller 1988; Radziwill et al. 1990; Beck and Nassal 2007). The 
priming domain is covalently bound to the 5’ end of the negative strand and initiates the 
synthesis which is carried out by the reverse transcriptase (Barthenschlager and Schaller 
1988; Weber et al. 1994). The RNase H domain digests selectively RNA from the DNA/RNA 
hybrid (Radziwill et al. 1990). 
 
 
 
Figure 2: Structure of HBV and subviral particles (filaments and spheres). a) Electron-
microscopical photograph of HBV-virions (left), HBsAg-filaments (middle) and HBsAg-spheres (right). b) 
Model of HBV and subviral particles consisting of the small (SHBs), middle (MHBs) and large (LHBs) proteins. 
HBs proteins are shown with the S, preS2 and preS1 domain (represented in red, orange and rose). 
Nucleocapsid (HBc, black). The viral polymerase is depicted with the reverse transcription (RT, dark green) and 
primer domain (pr, light green) (Kann and Gerlich 2005; modified). Encapsidated cellular proteins (protein 
kinase and chaperones) are omitted.  
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1.3.5 Genome 
The HBV genome is one of the smallest found so far and consists of a circular, partially 
double-stranded DNA. The longer, complete strand (negative polarity) comprises the 
complete coding capacity and is approx. 3.2 kb long depending on the genotype (Summers 
et al. 1975) (Fig. 3). The ends of this strand are not connected but show an overhang of 
about 8-10 nt at the 5´end (terminal redundancy) to which the primer domain of the viral 
polymerase covalently binds (Gerlich and Robinson 1980). This region is also spanned by 
the complementary plus-strand (Sattler and Robinson 1979) leading to a triplex strand areal 
(Will et al. 1987). The circularity of the genome does not originate from covalent closure but 
is rather caused by base pairing between both strands. The positive strand is incomplete 
with a constant 5’ end position and a variable 3’ end depending on how far it could be 
synthesized by the viral polymerase upon secretion (Hruska et al. 1977). The 5’ end is 
associated with an 18 nt long mRNA-like cap-structure (Seeger et al. 1986). The negative 
strand codes for four conserved, partially overlapping ORFs (Glebe 2006) which encode: 1) 
the core-protein and a soluble form of it (called HBeAg); 2) the DNA-polymerase with 
primase, reverse transcriptase and RNase H activity; 3) the surface proteins and 4) the X-
protein whose function is still not fully understood. The expression of the ORFs is regulated 
by several control elements with at least four promoters, two enhancers (Tang et al. 2001), 
the glucocorticoid-responsive element (GRE) and the negative regulating element (NRE) to 
which liver-and differentiation-dependent factors bind, leading to a hepatocyte-specific 
transcription and replication (Glebe 2006). There are additional regulatory elements at the 
mRNA-level, e.g. the posttranscriptional regulatory element (PRE), which prevents splicing 
of the transcripts and facilitates their transport into the cytoplasm and utilization (Huang 
and Liang 1993).  
Two identical sequence regions made of 11 nt (DR 1 and DR 2; direct repeats) are located in 
the genome and play an important role in virus replication (Will et al. 1987). 
Termination of transcription is achieved by a certain polyadenylation site resulting in a 
similar 3´end of all mRNAs (Ganem and Varmus 1987). The ε-signal at the 5´end of the 
pregenomic RNA participates together with the viral polymerase in the encapsidation 
process (Junker-Niepmann et al. 1990). 
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Figure 3: Genome structure of HBV. Inside, the four ORFs of the negative strand of HBV cccDNA are 
represented with the relevant start and stop codons: S-ORF with preS1-, preS2- and S-domain (red), Pol-ORF 
(green), C-ORF (dark grey) with preC (white), X-ORF (turquoise) with the respective promoters (light grey).The 
numbering indicates the base position from the EcoRI restriction site in the genome of HBV-genotype A2 
(AJ012207). Transcription start sites (    ) in the HBV cccDNA, mRNAs with polyA-tail (black), pregenomic-RNA 
(outmost circle). GRE: glucocorticoid responsive element; Enh: enhancer I and II; NRE: negative regulating 
element; PRE: posttranscriptional regulatory element; DR1 and DR2: direct repeats; ε: encapsidation signal; εII, 
ω and ф are sequence elements needed for genome maturation; (+): positive strand; (-): negative strand. (after 
Schaefer, Glebe and Gerlich, 2009; modified). 
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1.3.6 Viral life-cycle 
Initial attachment of HBV to susceptible hepatocytes occurs via heparan sulfate 
proteoglycans (HSPGs) that are presumably used to concentrate the virions on the cellular 
surface (Schulze et al. 2007; Leistner et al. 2008) (Fig. 4). Such primary attachment is 
relatively unspecific and of low-affinity (Marsh and Helenius 2006; Glebe and Urban 2007). 
Thereafter, HBV binds via its preS1 domain (amino acids 9-18 and 28-48 respectively) and 
the N-terminal myristic acid to (a) still unknown high-affinity receptor(s) that is (are) 
believed to actively promote further entry steps (Neurath et al. 1989; Pontisso et al. 1989; 
Le Seyec 1999; Glebe et al. 2003; Engelke et al. 2006; Glebe and Urban 2007; Leistner et al. 
2008). In addition to the receptor-binding site in the preS1-domain of the LHBs, a 
determinant of infectivity resides within the S-domain of LHBs possibly needed for fusion 
(Jaoude and Sureau 2005). It has been assumed that HBV enters the host cells via 
endocytosis, similar to DHBV, and is taken up into a still unknown cellular compartment 
(Köck et al. 1996; Glebe and Urban 2007). The exact point in time and site of nucleocapsid 
release is not fully understood, but for naked core particles, an active transport along 
microtubules towards the nucleus has been described (Rabe et al. 2006). HBV-capsids 
contain a NLS (nuclear localization sequence) for targeting the nucleus, where their 
subsequent import occurs through the nuclear pore complexes (NPCs) in an importin α/β-
mediated manner (Kann et al. 1999). NPCs are able to transport particles with a diameter of 
about 39 nm into the karyoplasm, therefore, HBV capsids can cross the nuclear pore 
without disassembly (Pante and Kann 2002). Furthermore, it was shown that disintegration 
of capsids takes place within the nuclear baskets thereby releasing the viral genome (Rabe 
et al. 2003). Inside the nucleus the relaxed circular DNA (rcDNA) of the virus is converted 
into the plasmid-like covalently closed circular DNA (cccDNA), the first marker of a 
productive infection. In the nucleus, the cccDNA molecule is associated with histones and 
exists as a minichromosome (Bock et al. 1994; Newbold et al. 1995). An integration of the 
viral DNA into the genome of the host is not part of the life cycle contrary to the 
retroviruses. However, a random integration of subgenomic DNA fragments can occur. 
From the cccDNA several genomic (pregenomic (pg) RNA) and subgenomic RNAs are 
transcribed by cellular RNA polymerase II (Rall et al. 1983). All HBV RNAs are 5´end-
capped and contain a PRE (see above) which prevents splicing (Schaller and Fischer 1991; 
Huang and Yen 1995). After export to the cytoplasm the pgRNA is translated into the 
polymerase (pol) and core proteins and serves as template for reverse transcription. The 
pgRNA interacts via its ε-signal with the polymerase and cellular chaperons thereby 
forming a complex which is encapsidated when sufficient core protein is available (Junker-
Niepmann 1990; Bartenschlager and Schaller 1992; Seifer et al. 1993; Hu and Seeger 1996). 
Within this immature capsid, reverse transcription and subsequent plus strand synthesis 
take place (Summers and Mason 1982). After completion of the negative strand synthesis, 
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the now mature capsid either re-migrates to the nucleus to amplificate/refill the 
intranuclear cccDNA-pool or interacts with HBsAg-containing membranes at the ER 
(Tuttleman et al. 1986; Wu et al. 1990). The other mRNAs (2.4 kb, 2.1 kb and 0.7 kb) are 
also transported into the cytoplasm and translated into the LHBs, MHBs, SHBs surface 
proteins or the HBx protein. Virus budding and secretion occurs via multivesicular bodies 
(MVBs) (Lambert et al. 2007), whereas the subviral particles leave the cell via the normal 
secretory pathway through ER and Golgi. 
 
 
 
 
Figure 4: Intracellular life cycle of HBV. ER: endoplasmatic reticulum, NPC: nuclear pore complex, Pol: 
polymerase. For simplification the synthesis of HBeAg and HBxAg is neglected. (after Kann and Gerlich, 2005; 
modified). 
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1.3.7 Model systems for HBV infection 
Due to the lack of appropriate animal models or cell lines, studies of the early stages of HBV 
infection were very difficult for a long time. HBV has a narrow host range and infects only 
humans or closely related species i.e. higher primates such as chimpanzees (Barker et al. 
1973). Therefore, classical laboratory animals, like mice or rats, are not suitable for HBV 
infection studies. The impropriety of using chimpanzees as model becomes apparent when 
the ethical as well as economic concerns are considered. Therefore, current in vivo models 
for investigating hepadnaviruses are ducks (DHBV infection) and woodchucks (WHV, 
GSHV and ASHV infection). Also the in vitro infection proves to be difficult because HBV 
infection does not only depend on the species origin but also on the differentiation state of 
the cells. Indeed, hepatoma cell lines such as HepG2 have been shown to bind HBV as well 
as produce virions upon transfection, but fail to support a complete infectious circle 
(Neurath et al. 1986; Shih et al. 1989; Qiao et al. 1994; De Falco et al. 2001; Rabe et al. 
2006). One exception is the HepaRG cell line which is susceptible for HBV infection after 
several weeks of differentiation with DMSO (Gripon et al. 2002). Primary hepatocyte 
cultures from ducklings (PDH) or embryonic hepatocytes from fertilized eggs are used to 
perform in vitro infection assays with DHBV (Glebe and Urban 2007). Primary human 
hepatocytes (PHH) can be infected with HBV but are not easy to handle and need certain 
growth factors for maintenance of their differentiated state. Furthermore, they are only 
available after surgical resection and show a heterogeneous quality since the state of health, 
age and gender of the donor varies (Glebe and Urban 2007). Alternatively, primary 
hepatocytes of the Southeast Asian tree shrew Tupaia belangeri (PTH), which is 
phylogenetically related to primates (Schmitz et al. 2000), can be used to study HBV 
infection in vitro (Su 1987) and also in vivo (Yan et al. 1996). The course of infection is 
analogous to that in human hepatocytes, but shows less variability and does not need 
growth or differentiation factors for successful infection (Glebe et al. 2003).  
 
 
 
 
 
 -Introduction-                                                    17 
1.4 Aim of this work 
To date, neither specific HBV receptors nor the exact mechanism for HBV entry into 
hepatocytes have been identified. In the present work the uptake mechanism of HBV should 
be investigated using primary hepatocyte cultures of Tupaia belangeri (PTH).  
 
Two main questions should be addressed: 
1. Does HBV infect its target cells by direct fusion with the plasma membrane or by an 
endocytic step? 
2. If HBV is taken up by an endocytic step, it should be analyzed which cellular 
pathway HBV is using for infecting liver-derived naturally susceptible hepatocytes 
and which organelles and components of the cellular transport machinery are 
involved.  
 
A comparison is made between the results obtained here with HBV and the entry 
characteristics of various control viruses with known entry and uptake mechanisms. 
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2. Material 
For the preparation of all solutions, water from an ion exchanger (Millipore) was used. 
 
2.1 Buffer, solutions and media 
2.1.1 Buffers 
 
 
2.1.2 Solutions 
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2.1.3 Media 
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2.2 Chemicals 
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2.3 Inhibitors 
2.3.1 Pharmacological inhibitors 
 
 
2.3.2 myr preS1-HBV peptide 
The peptide was synthesized and purified by S. Urban (Department of Biomolecular 
Chemistry of the Center for Molecular Biology, Heidelberg). 
 
2.4 Viruses 
2.4.1 HBV 
The virus preparations used in the present work were isolated from human HBV carrier 
plasma. All used ID´s were from genotype D: 
 
 
2.4.2 HBsAg 
 
 
2.4.3 Control viruses 
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Figure 5: Summary of the control viruses with their respective entry pathways (green) and the 
pharmacological inhibitors used to block these mechanisms (red). HRP: horseradish peroxidase; PM: 
plasma membrane; SeV: Sendai Virus; SFV: Semliki Forest Virus; SV40: Simian Virus 40.  
 
 
2.5 Cell Culture 
2.5.1 Cell culture systems  
 
 
2.5.2 Cells  
2.5.2.1 Primary Tupaia hepatocytes (PTH) 
For the different infection as well as binding and uptake experiments PTH were freshly 
isolated. The animals are from the animal breed that is kept by the Institute of Anatomy and 
Cell Biology at the Justus-Liebig-University in Giessen. 
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2.5.2.2 HepG2 
HepG2 cells were isolated from biopsy material of a human primary liver cancer (Aden et al. 
1979). The parenchymal cells are HBV-DNA free and have differentiated liver cell functions. 
 
2.5.2.3 HepaRG 
HepaRG cells were isolated from a human primary liver cancer (Gripon et al. 2002). The 
cells are HBV-DNA free and were obtained from S. Urban (Centre for Molecular Biology, 
Heidelberg). 
 
2.5.2.4 BHK 
BHK21 cells were obtained from the kidneys of one day old hamsters (Macpherson 
and Stoker, 1961). The cells were purchased from ATCC. 
 
2.5.2.5 CV-1 
CV-1 is an epithelial cell line of African green monkey kidney origin (Jensen et al. 1964). 
 
2.5.2.6 Huh-7 
Human hepatoma cell line was established from a Japanese isolate (Nakabayashi et al. 
1982). 
 
2.5.2.7 HeLa 
Cell line originating from a cervical biopsy of Henrietta Lacks whose initial two letters of 
first and last name were used for nomenclature (Gey 1952).  
 
 
2.6 Antibodies and –sera 
2.6.1 Primary antibodies and –sera 
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2.6.2 Secondary antibodies  
 
 
2.7 Fluorescent dyes 
 
 
2.8 DNA-and protein standards 
 
 
2.9 Plasmids 
 
 
2.10 Commercial kits 
 
 
2.11 PCR 
2.11.1 X-PCR 
The serum ID259 from a chronic HBV carrier (genotype D) was used as standard (U. Wend, 
personal communication). 
 
2.11.2 cccDNA-PCR 
The used standard plasmid “pBs HBV plasmid 991 T7 Dimer” was generated by cloning a 
HBV complete genome-dimer from pUC991 (HBV genotype A2) into the pBluescript II SK 
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vector (Stratagene). It was freshly diluted (107-100 GE) for each PCR run. Unreactive virion-
derived HBV DNA from plasma ID259 (see above) and additionally H2O served as negative 
controls.  
 
2.11.3 SV40-PCR 
Urine from a BK-virus carrier was used as standard (provided by Ch. Schüttler, Diagnostic 
Laboratory, Institute of Medical Virology, Giessen). 
 
2.11.4 Primer and Hybridisation probes (Hybprobes) 
Primer and Hybprobes for the X-and ccc-PCR were purchased from TIB MOLBIOL, SV40-
PCR primer were provided by the Diagnostic Laboratory (Institute of Medical Virology, 
Giessen). 
 
 
2.11.5 Mastermixes 
Enlisted Mastermix compositions count per test (10 µl in total) and are mixed with 10 µl   
(11 µl in case of SV40-PCR) purified DNA sample.  
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3. Methods 
3.1 Cell culture 
3.1.1 Isolation of PTH 
For each infection as well as binding and uptake assay PTH were freshly isolated. The 
isolation was carried out according to the two-step-collagenase-method (Seglen 1976). The 
animal was aerated for 5 min with CO2 according to the animal protection guidelines. After 
a negative eye reflex-test the animal´s death was assured by cervical dislocation. To dispose 
of coarse dirt particles and microbial contamination of the fur, the animal was shortly put in 
70% ethanol. Subsequently, the animal was placed with his back on a polystyrene pad and 
fixed on all limbs.  
After removing the fur from the abdomen and thorax, the abdomen was opened along the 
linea alba. The chest was removed and the liver including the portal vein (Vena portae) was 
uncovered. The vein was punctuated with a needle (22G, Braunüle, Vasocan) and its plastic 
tube was fixed with a small hemostat. The liver was perfused via a peristaltic pump with 5 
mM EGTA/HBSS for 20 min. The solution was free of calcium ions to destabilize cell-cell 
contacts and to prevent thrombosis of the hepatic capillaries. Successful perfusion was 
identified by brightening of the liver lobes. The liver was dissected and placed on a suction 
filter and further perfused with HBSS without EGTA for 10 min and then with a sterile 
filtered collagenase solution. With this solution, the liver was perfused in a recirculation 
system until the liver capsules became porous.  
The liver was transferred to a sterile cell culture dish and, after removal of the gall bladder, 
minced with scalpels. To finalize liver dissection, the tissue pieces were incubated with the 
collagenase solution in an Erlenmeyer flask (shaking with ~85 rpm) for 10-15 min at 37°C.  
For removal of non-perfused liver parts, the suspension was filtered through sterile gauze. 
The following steps were performed on ice and with ice cold materials. The filtrate was 
equally divided in four Falcon tubes (BD Biosciences) and then centrifuged (4°C, 40g, 6 
min), resulting in selective sedimentation of hepatocytes. Supernatants, containing mainly 
other cell types, were discarded and the pellets were resuspended in 10 ml DMEM, then 
further 30 ml DMEM were added. This washing step was repeated two times. After the third 
centrifugation, the hepatocytes were resuspended in 20-40 ml HGM with 10% FCS. To 
check cell viability a trypan blue-test was performed. 10 µl cell suspension was mixed with 
10 µl trypan blue on a glass slide and covered with a coverslip. After a successful isolation 
the viability of the cells is usually around 90-95%. Depending on the density of the cell 
suspension 2-3 drops were plated in 12-well cell culture dishes coated with Matrigel, 
resulting in about 105 hepatocytes per well. For binding and uptake assays, the cells were 
plated on coated coverslips (in 12-well dishes), for cccDNA assays in 6-well plates which 
were also coated with Matrigel. After 4 h at 37°C (5% CO2), the cells had attached. In order 
to achieve optimal re-differentiation of the hepatocytes, the FCS-containing medium was 
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removed and replaced by HGM (hepatocyte growth medium) without FCS. The cells were 
stored at 37°C (5% CO2) until the experiments were performed.  
 
3.1.2 Cultivation of stable cell lines 
3.1.2.1 BHK21, CV-1, HeLa, HepG2, Huh-7 
All stable cell lines were cultivated in 1-5% FCS/DMEM (37°C, 5% CO2) and splitted 
regularly before reaching a confluent state. 
 
3.1.2.2 HepaRG 
The hepatocyte precursor cell line HepaRG was differentiated to hepatocyte-/and epithelial-
like cells in a two-step process (König 2010). After being confluent, the cells were passaged 
three times with high cell density and finally seeded on coverslips, where they were cultured 
for 14 days in 1 ml growth medium with regular medium changes (every 2-3 days).  For 
differentiation, the cells were cultivated in growth medium containing 1-2% DMSO 
(differentiation medium) for further 2 weeks with regular medium changes. 
 
3.2 Virus preparation 
3.2.1 HBV 
Isolation and purification of HBV and HBsAg from plasma of chronically infected patients 
was done as described previously (Glebe et al. 2003; Grün-Bernhard 2008). Briefly, 30 ml 
HBV-positive plasma was layered on a sucrose cushion consisting of 6 ml 15% sucrose and  
2 ml 10% sucrose and ultracentrifuged for 18 h at 25,000 rpm at 10°C (SW 28.38 rotor; 
Beckman). The pellet, containing viral and subviral particles, was resuspended in 1 ml cold 
TNE and loaded on a discontinuous sucrose density gradient (15, 25, 35, 45 and 60% 
[wt/wt]/TNE) and again ultracentrifuged for 15 h (see above). The gradient was 
fractionated and the sucrose density of each fraction was determined with a refractometer. 
The concentration of virions was calculated as HBV genome equivalents (GE/ml) in virus-
containing fractions (40-45% sucrose) and determined by quantitative real-time PCR 
(LightCycler, Roche) using primers and hybridization probes against the HBV X-region as 
described previously (Jursch et al. 2002). Subviral HBsAg particles (fractions containing 
35-40% sucrose) were analyzed by SDS-polyacrylamid gelelectrophoresis (SDS-PAGE) and 
subsequent silver staining. 
 
3.2.2 SFV 
SFV was purified from infected cell culture supernatants by S. Broehl. 
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3.2.3 SV40 
CV-1 cells were cultivated in 5% FCS until they formed a confluent monolayer. Infection was 
done with 150 µl cell culture supernatant-derived SV40 in 1% FCS. When the cells showed 
first apoptotic signs, the supernantants were collected, viral genomes were purified (“High 
Pure Viral Nucleic Acid Kit”, Roche) and tested via PCR. 
 
3.2.4 SeV 
Stock solutions containing activated SeV (strain Z) was kindly provided by Prof. S. Pleschka, 
Institute of Medical Virology, JLU Giessen. 
    
3.3 Hemagglutination (HA)-assay 
SeV has the ability to agglutinate erythrocytes. To determine the SeV-titer a HA-assay was 
performed in a 96-well microtiter plate (round bottom). With 2 µl virus stock a serial 
twofold dilution series was made in PBS and applied to an equal volume of a 1% chicken 
erythrocytes solution (Donald and Isaacs 1954). The plate was stored for 1 h at 4°C. The 
dilution, at which still a complete agglutination occurred, equates to the HA-titer. The 
calculated HA-titer of the stock was 640/ml which corresponds to 6.4*109 virions/ml.   
 
3.4 Plaque assay 
3.4.1 SFV 
To determine the plaque-forming units per milliliter (PFU/ml) of SFV,  
BHK cells were seeded in a 12-well plate and cultivated for 20 h with 1% FCS/DMEM. The 
confluent monolayers were inoculated with 150 µl of a serial tenfold dilution of the virus 
stock (1 µl-0.00001 µl) for 1 h at 37°C. After three washing steps with wash buffer, the cells 
were overlaid with 1 ml 1% methylcellulose/ 1% FCS/DMEM and incubated 48 h at 37°C. 
Then, the cellulose medium was removed; the cells were gently washed twice with PBS and 
finally fixed with 3% PFA (30 min, room temperature). After washing once with H2O, the 
cells were stained with 1% crystal violet solution for 5 min, washed again with H2O and 
dried at room temperature before the plaques were counted. The PFU/ml was determined 
using following formula: PFU/ml = number of plaques x dilution factor x conversion to 1 
ml. The calculated PFU was 2*109/ml. 
 
3.5 Horseradish peroxidase (HRP)-Assay  
HRP was used as control substrate for cellular fluid phase uptake. PTH were preincubated 
with different pharmaceutical inhibitors (30 min at 37°C) or with HBV (30 min/60 min at 
4°C). Afterwards, the cells were replaced on ice, 0.025 mg/ml HRP was added and the cells 
were shifted again to 37°C for 3 h. Finally, the cells were washed five times (on ice with 
icecold wash buffer) and scraped off in 0.5 ml 0.1% Triton-X-100/PBS and centrifuged 
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(4°C, 5000g, 10 min). The pellets were discarded, 5 µl of the supernatants was pipetted into 
a microtiter plate and OPD-substrate (o-phenylenediamine; 100 µl) was added (room 
temperature, in the dark). After approx. 3 min the colouring reaction was stopped with      
50 µl 0.5 M H2SO4, the extinction was measured photometrically at 492 nm (reference-
wavelenght:  620 nm). 
 
3.6 Competent bacteria 
2 ml of an E.coli Mach1 (Invitrogen)-overnight culture were mixed with 40 ml LB-medium 
and incubated at 37°C (shaking) until the bacterial suspension reached an OD550 of approx. 
0.45. Afterwards, the culture was stored on ice for 15 min and henceforeward kept at 4°C. 
The bacteria were centrifuged (2500 rpm, 15 min), the pellet was resolved in 2 ml cold 
TFB1. 14 ml TFB1 were added, followed by a further incubation on ice (15 min). After 
another centrifugation (see above), the pellets were resuspended in 1.6 ml cold TFB2, 
incubated on ice again (15 min) and finally aliquoted and stored at -70°C. The competence 
of the bacteria for taking up plasmids was tested in a control transformation with the pcx-
plasmid conferring resistance against ampicillin. 
 
3.7 Transformation 
50 µl of the competent bacteria were thawed on ice, 50-100 ng of the desired plasmid DNA 
was added and the mixture was incubated for 20 min at 4°C. After heat shock (42°C, 30-45 
sec) and incubation (2 min, on ice), 950 µl LB-medium were added (incubation for 1 h at 
37°C; shaking). The bacteria were subsequently pipetted on LB-agar plates containing 
adequate antibiotics and were stored upside down overnight at 37°C. 
 
3.8 Plasmid isolation 
Preparation of pmaxGFP-plasmid DNA was performed with the “EndoFree Plasmid Maxi 
Kit” (Qiagen) according to the manufacturer´s instructions.  
 
3.9 Transfection 
3.9.1 FuGene 
PTH-transfection was performed 2 days after isolation (see Roche manual) using a 4:2 ratio 
(FuGene:DNA). The cells were incubated 48 h at 37°C and GFP-expression was checked 
microscopically. 
 
3.9.2 Amaxa 
Freshly isolated PTH (in suspension) were directly transfected with the 
Nucleofector®Device (courtesy of Prof. Rümenapf, Institute of Virology, Giessen) using the 
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“Mouse Hepatocyte Nucleofector Kit” (program “T-028”) according to the procedure 
outline. GFP-expression was checked after 48 h. 
 
3.9.3 Baculovirus-mediated transduction 
PTH were transduced with the BacMam reagent (Organelle Lights™ Endosomes RFP, 
Invitrogen) the day after isolation according to the manufacturer´s instructions. Rab5-
expression was examined 48 h afterwards. 
 
3.10 Binding and uptake studies 
3.10.1 HBsAg 
The HBsAg binding and uptake assays in PTH were performed analogous to the infection 
assays 2-3 days after isolation. PTH were washed icecold and incubated with 8ng purified 
HBsAg (2 h; 4°C). Afterwards, the cells were washed three times on ice and the different 
chemical inhibitors were added for 15-30 min. The 4°C- approaches were directly fixed on 
ice. The other cells were shifted to 37°C for 2 h in the continous presence of the inhibitors, 
fixed and stained for HBsAg using an anti-SHBs antibody. In some HBsAg-binding samples 
(4°C) the actin-cytoskeleton was additionally stained using “Alexa Fluor®647-Phalloidin”.  
 
3.10.2 Phagocytosis 
In order to examine the phagocytic potential of PTH, the cells were incubated with pHrodo 
E.coli BioParticles (Invitrogen) and HBsAg to examine whether colocalisation occurs. On 
day 3 after isolation, PTH were washed once and incubated with 40 µg pHrodo particles 
and ~8 ng purified HBsAg per coverslip for 2 h at 37°C, washed thrice and fixed. pHrodo 
conjugates are non-fluorescent outside the cell but fluoresce brightly inside acidic cellular 
compartments (product manual) therefore an extra immunostaining was not necessary. 
HBsAg was stained similar to the binding and uptake samples.  
 
3.11 Infection assays 
3.11.1 HBV 
The experimental setup of the infection assays is depicted in Fig. 6. After isolation, PTH 
were cultivated for 2-3 days in 600 µl HGM. The cells were preincubated with different 
chemical inhibitors (for 15-30 min at 37°C; see “Material” for the used concentrations). 
Subsequently, the cells were infected with different amounts of purified HBV virions from 
sera of chronic patients depending on the ID (see “Material”). The infection was blocked by 
addition of HBV myr preS1-peptide (100 nM) after 4 h, in case of HBsAg-assay with 
subsequent ELISA, or after 20 h p.i., when cccDNA of incoming viral particles was 
examined. The cells were washed three times. For the HBsAg-assay, the infected 
hepatocytes were cultivated for 14 days with regular medium-changes (600 µl HGM) every 
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3-4 days. Detection of newly produced HBsAg in the cell culture supernatants was done 
with an “in-house” sandwich-ELISA (see below). For cccDNA detection, the cells were lysed 
directly after the infection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Model system and experimental setup.  
a) After isolation of the liver, the hepatocytes were plated and cultivated for 2-3 days. 15-30 min before 
infection the cells were preincubated with different chemical inhibitors. A resulting infection was 
determined by detection of secreted HBsAg and cccDNA after 14 days and 20 h respectively. A detailed view 
of the infection period (red rectangle) is depicted in b). 
b) After the preincubation, the cells were infected with HBV for 4 h (HBsAg-assay) or 20 h (cccDNA). The 
infection was blocked by addition of HBV myr preS1-peptide. The cells were washed and either further 
incubated for 14 days (HBsAg-assay) or directly lysed for cccDNA detection. 
 
3.11.1.1 cccDNA isolation and Hirt extraction 
cccDNA of incoming viruses was isolated from infected PTH. All steps were performed on 
ice and with icecold materials. PTH were washed twice with PBS scraped off in 1 ml PBS. 
The cells were pelleted by centrifugation (2000 rpm, 2 min), the supernatants were 
discarded. 200 µl cell-lysis buffer were added, the tubes were gently vortexed and 
centrifuged (see above). The supernatants were discarded, the pellets (containing the 
nuclei) were frozen at -70°C. After thawing the pellets on ice, viral cccDNA was isolated by 
“Hirt-extraction” (Hirt 1969). 400 µl SDS/EDTA [0.6% (w/v)/10 mM EDTA] were added to 
the pellets and gently mixed. After 20 min at room temperature, NaCl (5 M; 100 µl) was 
added (the chromosomal DNA precipitated). The samples were stored for 20 h at 4°C and 
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then centrifuged (4°C, 14,000 rpm, 4 min). Supernatants comprising the viral cccDNA were 
additionally purified with the “High Pure Viral Nucleic Acid Kit” (Roche), before being 
applied in the PCR.  
 
3.11.1.2 Urea-Test 
As hepatocytes are the only cells producing urea, this organic compound was used to 
determine the viability of the PTH after each HBV infection assay. PTH-supernatants (100 
µl) were pipetted into a microtiter plate and 75 µl o-Phtalaldehyde and 75 µl NED-reagent 
were added. After 5 min at room temperature, the plate was measured photometrically at 
492 nm (reference-wavelenght: 620 nm). The obtained values were allocated with the 
amount of secreted HBsAg (ELISA). 
 
3.11.2 SFV 
BHK cells were seeded on glass coverslips and were grown for 20 h in 1% FCS/DMEM until 
they reached a confluency of about 70-80%. Similar to HBV infection or HBsAg binding and 
uptake assays, PTH were infected with SFV 2-3 days after isolation. The cells were washed 
once with wash buffer, then preincubated with different chemical inhibitors for 15-30 min 
at 37°C and infected with a MOI of 10 for 1 h (BHK) or with a MOI of 1000 (PTH) for 4 h at 
37°C. The cells were washed twice with wash buffer, once with glycin-buffer (pH 2.2) and 
finally three times with wash buffer. All washing steps were performed on ice and with 
icecold buffers. After an additional incubation period of 4 h at 37°C the cells were fixed with 
3% PFA and subsequently stained for newly synthesized viral E1/E2-protein. 
 
3.11.3 SV40 
CV-1 cells were plated on glass coverslips until they were 70-80% confluent after growing 
20 h in 1% FCS/DMEM. The cells were washed once (wash buffer) and preincubated with 
chemical inhibitors (15-30 min; 37°C). Then, the cells were infected with 3.00E+03 GE for 
10 h in the continous presence of the inhibitors. The cells were washed three times on ice 
with icecold wash buffer and then fixed with 3% PFA. For immunostaining, a monoclonal 
anti-large T- antigen antibody was used. 
  
3.11.4 SeV 
CV-1 cells were grown to a confluency of 70-80% with 1% FCS/DMEM, washed once with 
wash buffer, preincubated with the distinct chemical inhibitors and infected with approx. 
107 virions for 8 h. The cells were washed thrice with cold wash buffer on ice, fixed and 
finally immunostained with an anti-SeV antiserum.   
 
 
 -Methods-                                                    33 
3.12 ELISA 
96-well microtiter plates were coated with 100µl (1µg/ml) anti-HBs-antibody (C20/2) for 
48 h at 4°C. The following and all subsequent washing steps were done with an automatic 
ELISA washer (Tecan). The used program consisted of four washing steps (2x 0.1% 
tween/PBS and 2x PBS; 300 µl each). The wells were blocked with 10% FCS/TNE (200 
µl/well; 2 h at 37°C, shaking). After washing, 100 µl cell culture supernatants of infected 
cells were pipetted into the wells. For quantification, purified HBsAg served as standard and 
was diluted in 1% caseine/PBS (10-0.3 ng/ml HBsAg). The plates were incubated for 20 h at 
4°C. Before and after incubation with a biotinylated anti-HBs-antibody (1:100 in 0.1% 
casein/PBS; 100µl; 1 h at 37°C, shaking) the plates were washed again. Streptavidine-POD 
was added (1:500 in 0.1% casein/PBS; 100 µl; 0.5 h at 37°C, shaking) the plates were 
washed and 100 µl OPD-substrate were added (room temperature, in the dark). The 
reaction was stopped with 50 µl 0.5 M H2SO4. Extinction of the colored substrate was 
measured photometrically at 492 nm (reference-wavelenght: 620 nm). 
 
3.13 Immunostaining 
At the end of the infection, binding and uptake studies, the cells were fixed with 3% PFA, 
permeabilized with 0.2% Triton-x-100 and blocked with 5% goat-serum. All steps were 
performed at room temperature for 30 min with 1-2 washing steps in between. Primary 
antibodies were incubated for 1.5 h at 37°C. Before and after the incubation with the 
secondary antibodies for 1 h at 37°C, the cells were washed five times. For nucleus-staining, 
the cells were incubated with DAPI for 5 min at room temperature, washed five times and 
finally mounted on a glass slide using Mowiol.  
 
All immunostained samples were analyzed with a Leica TCS SP5 confocal microscope. 
 
3.14 PCR 
Viral DNA was purified with the “High Pure Viral Nuceleic Acid Kit” (Roche) according to 
the manufacturer´s manual and then applied in the PCRs. 
 
3.14.1 X-PCR 
Table 1: LightCyler program for the X-PCR: 
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3.14.2 cccDNA-PCR 
The used PCR specifically discriminates between cccDNA and genomic DNA due to primer 
that bind before and after the nick-and-gap structure and an optimized protocol with rapid 
temperature changes (Glebe et al. 2003). 
 
 Table 2: LightCycler program for the ccc-PCR: 
 
 
3.14.3 SV40-PCR 
 
Table 3: LightCyler program for the SV40-PCR: 
 
 
3.14.4 Agarose gel electrophoresis of PCR products 
After the PCR runs, the capillary contents were centrifuged into an Eppendorf tube, mixed 
with 6x SDS-containing Agarose-samplebuffer and loaded on a 2% agarose gel (with 
ethidium bromide). pUC Mix 8 DNA marker was used for the cccDNA-and the SV40-gel. 
The separation was carried out at 150V for 30 min. 
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4. Results 
4.1 HBsAg binding and uptake in PTH  
To study the early events of HBV infection, the binding and uptake characteristics of 
purified HBV subviral particles (HBsAg) in PTH were examined at first.  
Fig. 7 shows immunostaining of HBsAg after incubation of purified subviral particles with 
PTH at 4°C. HBsAg strongly bound to cellular membrane protrusions (a, open arrowheads) 
and, to a lesser extent, to non-protruding structures on the cellular surface. However, not all 
hepatocytes were equally covered with HBsAg, instead an uneven distribution within the 
hepatocyte population was observed. In some cases one cell bound HBsAg and its next 
neighbor not (b and c, open arrowheads). Furthermore, on the single-cell-level the HBsAg-
signal showed a distinct staining pattern in certain membrane patches. There was no 
noticeable attachment of HBsAg to bile canaliculi which are thin tubes formed at the lateral 
surfaces between adjacent hepatocytes that can be visualized by actin staining (c, grey 
arrowhead). Besides a binding to PTH, also an uptake into vesicular-like compartments was 
observed after warming to 37°C (d and e, full arrowheads).  
 
 
Figure 7: Binding and uptake of HBsAg subviral particles by PTH. The cells were incubated with 
HBsAg (8ng) at 4°C for 2 h and either fixed directly (4°C, a-c) or shifted to 37°C for 2 h (d+e) before 
immunostaining for SHBs (green) and actin (red) as well as DAPI-staining of nuclei (blue) was performed. f) 
negative control without HBsAg. Scale bars: a) 25 µm, b, d, f) 50 µm, c + e) 10 µm. 
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4.2 Endocytosis vs. plasma membrane fusion of HBV and control viruses 
To learn more about the entry of HBV into PTH, certain viruses with different well-known 
uptake pathways were used as controls. The results from these experiments were compared 
with HBV.  
 
4.2.1 Semliki Forest Virus (SFV) 
SFV, an enveloped Alphavirus, is known to be internalized from the cell surface by CME 
(Helenius et al. 1980; Glomb-Reinmund and Kielian 1998).  
SFV infects many different cell types, including PTH (Fig. 8c and d). A striking different 
staining pattern of newly synthesized viral surface proteins was observed in the two cell 
types: in BHK (baby hamster kidney) cells the E1/E2-proteins are distributed within the 
complete cytoplasm with larger accumulations in the vicinity of the nuclei (a and b), 
whereas in PTH they are mainly located directly below the plasma membrane or in close 
proximity to the nucleus (d).  
 
 
Figure 8: Semliki Forest Virus infects BHK and PTH. Th cells were incubated with MOI 10 (BHK) or 
MOI 1000 (PTH) and stained for newly produced viral E1/E2-protein (red) after 5 h p.i. (BHK) and 8 h p.i. 
(PTH) respectively. a) BHK (b: z-stack image), c) PTH (d: z-stack image). Nuclei (blue). Scale bars: 50µm.  
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4.2.2 Simian Virus 40 (SV40) 
The uneneveloped SV40 is a well-studied member of the Polyomaviridae (Pelkmans et al. 
2001). The entry process of SV40 begins with the adsorption of the virion to MHC class I 
molecules on the cellular surface (Stang et al. 1997; Norkin 1999) before being internalized 
via caveolar/lipid raft-mediated endocytosis (Anderson et al. 1996; Pelkmans et al. 2001). 
In cells devoid of cav-1 the virus uses a different, lipid raft-dependent pathway which also 
leads to a productive infection (Damm et al. 2005). To investigate whether PTH could also 
be infected with SV40, the cells were inoculated with 3.00E+03 GE (genome equivalents) 
for 72 h and subsequently immunostained for SV40 early large T-antigen expression. Fig. 9 
shows that in contrast to CV-1 cells (a) SV40 infection was not supported by PTH (b). For 
this reason SV40 could unfortunately not be used as a direct control for e.g. caveolin-
mediated entry in PTH. Nevertheless it was utilized at least in CV-1 cells to analyze potential 
inhibitory effects on the entry of unenveloped viruses and to prove the impact of certain 
pharmaceutical inhibitors on special cellular entry routes (see chapter “4.7 Retrograde 
pathway”). 
 
 
Figure 9: SV40 infects CV-1 cells but not PTH. Cells were infected with 3.00E+03 GE SV40 for 10 h (CV-
1) or 72 h (PTH) following detection of early large T-antigen expression (red) by immunostaining. DAPI-staining 
of nuclei (blue). a) CV-1 cells, b) PTH. Scale bars: 250 µm. 
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4.2.3 Sendai Virus (SeV) 
Fusion of the enveloped SeV (Paramyxoviridae, Genus Respirovirus) occurs directly at the 
plasma membrane (PM) at neutral pH (Bossart 2010). SeV is a common pneumotropic 
pathogen that is endemic in many rodent colonies in the world (Faisca and Desmecht 
2007). In natural infections, SeV replicates primarily in the respiratory epithelium but since 
the viral hemagglutinin-neuraminidase (HN) binds to sialic acid-containing gangliosides, 
which are ubiquitously expressed on the surface of all eukaryotic cells, other organs are 
potentially permissive for infection (Ito et al. 1983; Bitzer et al. 1997).  Fig. 10 demonstrates 
that in vitro, besides CV-1 cells, also PTH can be infected with SeV, though with less 
productivity. In both cases virtually all cells show a cytoplasmic staining of newly 
synthesized viral proteins. 
 
 
 
 
 
Figure 10: SeV infects CV-1 cells and PTH. Cells were infected with 107 virions for 8 h and stained for 
newly produced SeV proteins using a polyclonal anti-SeV antiserum (red). DAPI-staining of nuclei (blue).  a) 
CV-1 cells, b) PTH. Scale bars: 50 µm. 
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4.2.4 Inhibitors used to block certain cellular endocytic steps 
Medium containing high concentrations of sucrose was used to differentiate between 
endocytosis and direct fusion with the PM as possible mechanism for HBV entry. The 
above-mentioned viruses served as controls. Transient treatment with hypertonic sucrose 
prevents CME due to dispersion of CCPs on the PM (Heuser and Anderson 1989). To test 
whether this has any effect on SFV infection in BHK and PTH, the cells were preincubated 
with different sucrose concentrations (0.125 M, 0.25 M and 0.5 M) and subsequently 
infected with the virus.  Fig. 11 and 12 show that in both cell types a dose-dependent 
inhibition of the SFV infection occurred. It is noteworthy that in PTH, even when no 
inhibitors are present, only approx. 30% of the cells are infected with SFV. 
 
 
 
Figure 11: Dose-dependent inhibition of SFV infection of BHK cells by sucrose. The cells were 
preincubated with different sucrose concentrations (15 min, 37°C) and subsequently infected (MOI 10). The cells 
were fixed 5 h p.i. and newly synthesized SFV E1/E2-protein (red) and nuclei (blue) were stained. a) untreated 
cells without inhibitor, b) 0.125 M sucrose, c) 0.25 M sucrose, d) 0.5 M sucrose, e) uninfected control. f) Three 
randomly chosen fields were analyzed for the amount of E1/E2 positive cells. Data are expressed as percentage ± 
SD of E1/E2 positive cells in untreated cells. Scale bars: 50µm. 
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Figure 12: Sucrose inhibits SFV infection of PTH in a dose-dependent manner. The cells were 
preincubated with different sucrose concentrations (15 min, 37°C) and subsequently infected (MOI 1000). The 
cells were fixed 8 h p.i. and newly synthesized SFV E1/E2-protein (red) and nuclei (blue) were stained. a) 
untreated cells without inhibitor, b) 0.125 M sucrose, c) 0.25 M sucrose, d) 0.5 M sucrose, e) uninfected control. 
f) Three randomly chosen fields were analyzed for the amount of E1/E2 positive cells. Data are expressed as 
percentage ± SD of E1/E2 positive cells in untreated cells. Scale bars: 50µm. 
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It is known by now that treatment with sucrose does not constrict CME alone but also 
affects clathrin-independent (CI)-uptake and endocytosis in general (Nieland et al. 2005; 
Ivanov 2008). Using similar concentrations of hypertonic sucrose, the SV40 infection was 
also affected (Fig. 13) with a virtually complete reduction at 0.5 M sucrose (d).  
 
 
 
Figure 13: Inhibition of SV40 infection in CV-1 cells by sucrose. Cells were preincubated with different 
sucrose concentrations (15 min, 37°C), subsequently infected with 3.00E+03 GE SV40 and stained for early 
large T-antigen expression (red) and nuclei (blue). a) untreated cells without inhibitor, b) 0.125 M sucrose, c) 
0.25 M sucrose, d) 0.5 M sucrose, e) uninfected control. f) Five randomly chosen fields were analyzed for the 
amount of cells expressing large T-antigen. Data were expressed as percentage ± SD of T-antigen expression in 
untreated cells. Scale bars: 50µm. 
 
 
 
 
In contrast, SeV infection was not impaired in CV-1 cells or in PTH (Fig. 14 and 15). Even at 
the highest sucrose concentration of 0.5 M all cells are infected to a certain extent. The only 
visible difference in comparison with the positive control is a more punctuated pattern 
rather than a smooth staining throughout the complete cytoplasm (Fig. 14d and Fig. 15d). 
 
 
 
 -Results-                                                 42 
 
Figure 14: Hypertonic sucrose does not inhibit SeV infection of CV-1 cells. Cells were preincubated 
with different sucrose concentrations (15 min, 37°C), subsequently infected with 107 virions and stained for 
newly produced SeV proteins (red) and nuclei (blue) 10 h p.i. a) untreated cells without inhibitor, b) 0.125 M 
sucrose, c) 0.25 M sucrose, d) 0.5 M sucrose, e) uninfected control. Scale bars: 50µm. 
 
Figure 15: Hypertonic sucrose does not inhibit SeV infection of PTH. Cells were preincubated with 
different sucrose concentrations (15 min, 37°C), subsequently infected with 107 virions and stained for newly 
produced SeV proteins (red) and nuclei (blue) 10 h p.i. a) untreated cells without inhibitor, b) 0.125 M sucrose, 
c) 0.25 M sucrose, d) 0.5 M sucrose, e) uninfected control. Scale bars: 50 µm. 
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Next, the effect of sucrose on uptake of HBsAg was studied by confocal microscopy. PTH 
with prebound HBsAg (4°C) were exposed to different hypertonic sucrose concentrations 
and shifted to 37°C for additional 2 h. Afterwards, the cells were fixed and subviral particles 
were immunostained with an anti-SHBs antibody. Fig. 16 illustrates cut views through z-
stack-images of single cells. Even after 2 h at permissive temperature for endocytosis a 
certain amount of HBsAg still remained bound at the plasma membrane (open 
arrowheads). However, also vesicular-shaped staining inside the cells could be observed 
(full arrowheads) the number of which was reduced with increasing sucrose concentrations. 
Full inhibition of uptake was observed at 0.5 M sucrose. The inhibitory effect of hypertonic 
sucrose treatment on HBsAg uptake had direct effect on HBV infectivity for PTH. Infection 
was inhibited with hypertonic medium in a dose-dependent manner (Fig. 17) as determined 
by detection of cccDNA formation of incoming virus particles after 20 h (a) and newly 
secreted HBsAg after 14 days (b).  
 
 
Figure 16: HBsAg uptake in presence of hypertonic sucrose. PTH were preincubated with 8ng HBsAg 
(4°C, 2 h) before different sucrose concentrations were added and the cells were shifted to 37°C for 2 h. The cells 
were stained for SHBs (green) and nuclei (blue). a) untreated cells without inhibitor, b) 0.125 M sucrose, c) 0.25 
M sucrose, d) 0.5 M sucrose, e) negative control without HBsAg. Confocal images show a cut view through z-
stack-images of single cells. 
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Figure 17: Effect of sucrose on HBV infection of PTH. The cells were preincubated with different sucrose 
concentrations (15 min, 37°C) and afterwards infected with purified plasma-derived HBV virions (2,00E+07 
GE). cccDNA-formation of incoming HBV particles was determined 20 h p.i. by PCR and detected by gel 
electrophoresis (a). Newly secreted HBsAg was measured 14 days p.i. (b). Data in b) represent the average ± SD 
of three independent experiments. Cellular viability was checked via measurement of secreted urea (the positive 
control without sucrose was set as 100% viability) and revealed smaller effects than on infectivity: 0.125 M 
(77%), 0.25 M (68%) and 0.5 M (59%). 
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4.3 Dynamin-dependent endocytosis 
4.3.1 Clathrin-mediated endocytosis 
CME is a very important endocytic mechanism with an absolute requirement for dynamin 
(Doherty and McMahon 2009). Since 2007, a novel specific inhibitor of dynamin is 
available: Dynasore interferes with the GTPase activity of dynamin and was shown to block 
dynamin-dependent internalization of transferrin, a known cargo of CME (Macia et al. 
2006). Fig. 18 illustrates that SFV infection was completely abolished when BHK cells were 
preincubated with Dynasore (b). The same was true for PTH (Fig. 19b) showing that also in 
these cells the GTPase activity of dynamin was completely inhibited with this drug. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: SFV infection of BHK cells is inhibited by Dynasore. 
Prior infection (MOI 10) the cells were pretreated with Dynasore (100 µM, 
15 min, 37°C), which was also present during the inoculation period. The 
cells were fixed 5 h p.i. and stained for newly produced SFV E1/E2-protein 
(red) and nuclei (blue). a) untreated cells without inhibitor, b) Dynasore-
treated cells, c) uninfected control. d) Three randomly chosen fields were 
analyzed for the amount of E1/E2 positive cells. Data are expressed as 
percentage ± SD of E1/E2 positive cells in untreated cells. Scale bars: 50µm. 
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Figure 19: Impact of Dynasore on SFV infection of PTH. Cells were 
preincubated with 100 µM Dynasore (15 min, 37°C), subsequntly infected 
(MOI 1000), fixed 8 h p.i. and stained for newly produced SFV E1/E2-
protein (red) and nuclei (blue). a) untreated cells without inhibitor, b) 
Dynasore-treated cells, c) uninfected control. d) Three randomly chosen 
fields were analyzed for the amount of E1/E2 positive cells. Data are 
expressed as percentage ± SD of E1/E2 positive cells in untreated cells. Scale 
bars: 50µm. 
 
 
 
SV40 infection is dependent on dynamin when using the caveolae-mediated endocytosis 
into target cells. Using Dynasore to inhibit the GTPase activity of dynamin in CV-1 cells, 
SV40 infection was drastically reduced (Fig. 20) confirming earlier results with dominant 
negative-dynamin II (Pelkmans et al. 2002). In contrast to this, the direct fusion of SeV 
with the plasma membrane was shown to be independent of the activity of dynamin since 
the infection was not impaired by Dynasore (Fig. 21 and 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: SV40 infection of CV-1 cells is dynamin-dependent. 
Prior infection with 3.00E+03 GE of SV40, the cells were preincubated with 
100 µM Dynasore (15 min, 37°C). Staining for early large T-antigen 
expression (red) and nuclei (blue) was performed 10 h p.i. a) untreated cells 
without inhibitor, b) Dynasore-treated cells, c) uninfected control. f) Five 
randomly chosen fields were analyzed for the amount of cells expressing 
large T-antigen. Data were expressed as percentage ± SD of T-antigen 
expression in untreated cells. Scale bars: 50µm. 
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Figure 21: Dynamin-independent SeV infection of CV-1 cells. The cells were preincubated with 
Dynasore (100 µM) before being inoculated with 107 virions and stained for newly produced SeV proteins (red) 
and nuclei (blue) 10 h p.i. a) untreated CV-1 cells without inhibitor, b) Dynasore-treated CV-1 cells. Scale bars: 
50 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Dynamin-independent SeV infection of PTH. PTH were preincubated with Dynasore        
(100 µM) before being inoculated with 107 virions and stained for newly produced SeV proteins (red) and nuclei 
(blue) 10 h p.i. a) untreated PTH without inhibitor, b) Dynasore-treated PTH. Scale bars: 50 µm. 
 
 
 
 
 
 
 
 
 
Both, the direct uptake of HBsAg and HBV infection in PTH were not affected by Dynasore 
as vesicular accumulations were visible inside the cytoplasm (Fig. 23b, full arrowheads) and 
the markers of HBV infection (secreted HBsAg and cccDNA) showed no difference in 
comparison with the positive control (Fig. 24).  
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Figure 23: HBsAg uptake in presence of Dynasore. PTH were preincubated with 8 ngHBsAg (4°C, 2 h) 
before 100 µM Dynasore was added and the cells were shifted to 37°C for 2 h. The cells were stained for SHBs 
(green) and nuclei (blue). a) untreated cells without inhibitor, b) Dynasore-treated cells, c) negative control 
without HBsAg. Confocal images show a cut view through z-stack- images of single cells. 
 
 
 
 
 
 
 
 
 
Figure 24: HBV infection of PTH in presence of Dynasore. 
The cells were preincubated with Dynasore (100 µM, 15 min, 37°C) 
and afterwards infected with purified plasma-derived HBV virions 
(2,00E+07GE). cccDNA-formation of incoming viral particles was 
determined 20 h p.i. by PCR and detected by gel electrophoresis 
(a). Newly secreted HBsAg was measured 14 days p.i. (b). Data in b) 
are means of triplicate experiments ± SD. 
 
 
 
 
 
 
4.3.2 Caveolin-mediated uptake 
An endocytotic uptake route independent of clathrin but dependent on dynamin is 
displayed by caveolae-mediated endocytosis. Caveolae are enriched in caveolins, esp. 
caveolin-1 (cav-1), sphingolipids and cholesterol and are present on many cell types (Mayor 
and Pagano 2007). Sterol-binding drugs, e.g. Nystatin or Methyl-beta-cyclodextrin (MßCD), 
that sequester cholesterol are probably the most effective way to disrupt caveolar function 
(Sieczkarski and Whittaker 2002).  
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Since SV40 leaves the plasma membrane in cav-1-containing vesicles before entering larger 
non-acidic organelles, called caveosomes (Pelkmans et al. 2001), therefore the infection 
process can be blocked by preincubating the host cells with MßCD (Fig. 25). In contrast, 
cholesterol depletion from PTH membranes using MßCD did not affect HBV infection, 
suggesting a lipid raft independent uptake mechanism (Fig. 26, see also Bremer et al. 
2009). Similar results were obtained in the DHBV model system (Funk et al. 2008).  
 
 
 
 
 
 
 
 
 
 
Figure 25: SV40 infection is dependent on cellular cholesterol. 
CV-1 cells were preincubated with 3 mM MßCD for 60 min (37°C) and 
washed thrice before infection with 3.00E+03 GE SV40. Immunostaining 
for early large T-antigen expression (red) and DAPI-staining of nuclei (blue) 
was performed 10 h p.i. a) untreated cells without inhibitor, b) MßCD-
treated cells, c) uninfected control. d) Five randomly chosen fields were 
analyzed for the amount of cells expressing large T-antigen. Data were 
expressed as percentage ± SD of T-antigen expression in untreated cells. 
Scale bars: 50µm. 
 
 
 
 
 
 
 
Figure 26: HBV infection is not dependent on 
cellular cholesterol. PTH were preincubated with the 
indicated concentrations of MßCD for 60 min (37°C) and 
washed thrice before infection with HBV (2.00E+07 GE) 
for 16h (37°C). Newly secreted HBsAg was measured 14 
days p.i. 
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In contrast to that, Macovei et al. hypothesized that HBV requires cav-1-mediated entry for 
productive infection of HepaRG cells (Macovei et al. 2010). To follow this up, the cav-1-
content of PTH should be compared with other cell types and especially with HepaRG cells 
which become permissive for HBV infection after several weeks of differentiation with 
DMSO (Gripon et al. 2002). The resulting immunostaining, depicted in Fig. 27, shows that 
PTH obviously do not express cav-1 as judged by the absence of protein staining (a). In 
contrast, HepaRG cells showed a strong cav-1-expression in undifferentiated condition (b) 
which was even more increased in differentiated cells (c). Other hepatic cell lines such as 
HepG2 (d) and Huh7 (e) lacked the cav-1-signal, and only the fibroblast cells CV-1 showed 
small amounts of cav-1 (f). 
 
Figure 27: Cav-1 expression in different cell types. PTH were fixed three days after isolation. All other 
cell lines were cultivated over several weeks before being fixed the day after splitting. Cav-1 (red), nuclei (blue). 
a) PTH, b) HepaRG (undifferentiated), c) HepaRG (differentiated for 14 days), d) HepG2 cells, e) Huh7 cells,     
f) CV-1 cells. Scale bars: 50 µm. 
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Depletion of cholesterol from the HBV envelope using MßCD had no influence on viral 
binding to PTH as shown in confocal microscopy (Fig. 28): MßCD-treated HBV virions (a) 
bound to a similar extent to PTH as untreated HBV particles (b) and were detected in 
distinct areas of the PM (open arrowheads). However, cholesterol-depletion led to a 
reduced infectivity of HBV virions (Fig. 29) indicating that cholesterol in the viral envelope 
is essential during early steps of HBV infection (see also Bremer et al. 2009).  
 
 
 
Figure 28: Influence of MßCD on HBV binding to PTH. Highly purified plasma-derived HBV virions 
were incubated with 10 mM MßCD for 1 h at 37°C. The cells were incubated for 1 h at 4°C with MßCD-treated 
HBV (a) or with untreated HBV (b); c) negative control, followed by immunostaining for SHBs (red) and 
asialoglycoprotein receptor (green). Scale bars: 50 µm. (published in: C. M. Bremer, C. Bung, N. Kott, M. Hardt 
and Dieter Glebe (2009). "Hepatitis B virus infection is dependent on cholesterol in the viral envelope." Cellular 
Microbiololgy 11(2), 249-60. modified) 
 
 
 
 
 
 
 
Figure 29: Effect of MßCD treatment on HBV infectivity. Highly 
purified plasma-derived HBV virions were incubated with 10 mM MßCD for 
1 h at 37°C and the cells were infected for 16 h (37°C) with untreated or 
MßCD-treated virions. Newly secreted HBsAg was measured 14 days p.i. 
 
 
 
 
 
 
 
 
 
 -Results-                                                 52 
4.4 Dynamin-independent endocytosis 
4.4.1 Phagocytosis 
Phagocytosis is a specific form of endocytosis and is carried out primarily by specialized 
cells, such as macrophages, monocytes and neutrophils (Conner and Schmid 2003). It is 
critical for the uptake and degradation of pathogens, e.g. bacteria and parasites (Aderem 
and Underhill 1999) and has recently been shown  to be an infection route of the large 
Mimivirus in amoebal macrophages (Ghigo et al. 2008). Since most cells have at least some 
phagocytic capacitiy (Aderem and Underhill 1999) it was tested whether phagocytosis 
occurs in PTH and if it displays a potential entry mechanism for HBV. The cells were 
incubated with purified HBsAg and labeled E.coli (pHrodo) BioParticles and checked for 
possible colocalization. E.coli conjugated with pHrodo showed no fluorescence inside acidic 
compartments of PTH, which showed staining of bound and internalized HBsAg (Fig. 30, 
white arrowheads). However, in smaller, non-parenchymal cells adjacent to hepatocytes a 
red staining of the E.coli particles was detectable, indicating phagocytosis (grey 
arrowheads) whereas a specific HBsAg signal was absent in these cells.   
 
 
 
Figure 30: Role of phagocytosis in PTH. PTH were incubated with 8 ng HBsAg and pHrodo E.coli 
particles for 2 h at 37°C, then extensively washed, fixed and stained for SHBs (green) and nuclei (blue). pHrodo 
labeled E.coli (red). a) and b) show representative images of two independent experiments. Scale bars: 25 µm. 
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4.4.2 Macropinocytosis 
Macropinocytosis is an actin-driven endocytic process that is used to internalize large 
amounts of fluids and solutes. In the majority of cases it is transient, growth-factor induced 
and involves protrusions of the plasma membrane in form of lamellipodia, circular ruffles 
and blebs (Doherty and McMahon 2009; Mercer and Helenius 2009). Na+/H+ exchangers 
play an important role in the process of ruffling (Mercer and Helenius 2009) and therefore 
EIPA (5-[N-ethyl-N-isopropyl] amiloride), a selective blocker of the Na+/H+-antiport, was 
used to study the effect on the fluid phase uptake. Furthermore, Blebbistatin (which inhibits 
bleb formation), Dynasore, sucrose, the actin-stabilizing/-depolymerizing drugs, 
Jasplakinolide (Jas) and Cytochalasin D (CytoD), as well as Brefeldin A (BFA) were used to 
check a possible impact on the process of fluid phase uptake in PTH. BFA has been shown 
to enhance macropinocytosis in CHO cells (Kumari and Mayor 2008), therefore a potential 
influence in PTH should be tested. Horseradish peroxidase (HRP) served as fluid phase 
marker (Haigler et al. 1979). 
Fig. 31a shows that preincubation with EIPA lead to a 60% reduction of HRP uptake 
whereas treatment with Blebbistatin and Dynasore had no effect on the internalization. 
Sucrose blocked the uptake in a dose-dependent manner (b) and also Jas and CytoD (see 
also chapter 4.6) reduced the HRP uptake similar to EIPA (c). Preincubation with the fungal 
metabolite BFA lead to an enhancement of fluid phase endocytosis (d). 
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Figure 31: Impact of different chemical inhibitors on fluid phase uptake of HRP in PTH. Cells were 
preincubated with the indicated inhibitors (EIPA: 100 µM, Blebbistatin: 100 µM, Dynasore: 100 µM, 
Jasplakinolide: 1 µM, Cytochalasin D: 50 µM, Brefeldin A: 0.1 mg/ml, sucrose: as indicated) for 30 min at 37°C. 
HRP (0.025 mg/ml) was added and incubated for 3 h at 37°C or 4°C. After extensive washing on ice the cells 
were lysed and cytosolic HRP-signal was measured. a+b) The values are means ± SD of two independent 
experiments (four values in total), c+d) represent single experiments (three values in total).  
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Since Adenovirus type 2 (Ad2) transiently stimulates macropinocytosis (Meier et al. 2002) 
it was tested whether HBV has the same capability. Preincubation of the cells with purified 
virions does not have a stimulating effect on fluid phase uptake regardless of whether the 
incubation lasted 0.5 or 1 h (Fig. 32a). 
Several pathogens do not only trigger macropinocytosis but also exploit this pathway to 
invade their host cells, e.g. Vaccinia Virus and Ad2/Ad5 (Meier and Greber 2004; Mercer 
and Helenius 2008). Endocytotic uptake and infection of those viruses can be blocked by 
EIPA (Kälin et al. 2010; Mercer and Helenius 2008). In contrast, HBV infection was not 
impaired by this inhibitor (Fig. 32 b+c). 
 
 
 
 
Figure 32: Effect of HBV on fluid phase uptake and impact of EIPA on HBV infection of PTH. a) 
Cells were incubated with purified plasma-derived HBV virions (2.00E+07 GE) for the indicated times in the 
cold, washed three times on ice and warmed with HGM medium containing 0.025mg/ml HRP for 3 h at 37°C. 
After extensive washing on ice the cells were lysed and cytosolic HRP-signal was measured. b+c) Cells were 
preincubated with 100 µM EIPA (30 min, 37°C) and afterwards infected with purified plasma-derived HBV 
virions (2.00E+07 GE). cccDNA-formation of incoming viral particles was determined 20 h p.i. by PCR and 
detected by gel electrophoresis (a). Newly secreted HBsAg was measured 14 days p.i. (b). Data represent the 
average ± SD of two (a) and three (c) independent experiments respectively. 
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4.5 pH-dependence of viral infection 
Penetration of enveloped viruses occurs by fusion of the viral with the host cell membrane 
which can take place at the PM or at intracellular membranes (Kielian and Rey 2006). This 
fusion can be triggered either by receptor binding at neutral pH, e.g. SeV and HSV-1, or by 
mildly acidic pH within endosomal compartments (Smith and Helenius 2004; Marsh and 
Helenius 2006) which is established by the action of vacuolar-type ATPases (v-ATPases) 
(Jefferies et al. 2008; Huss and Wieczorek 2009). Lysosomotropic agents such as 
Bafilomycin A1 (BafA1), a specific inhibitor of v-ATPases, the weak base NH4Cl or the 
ionophore Monensin raise the pH in early endosomes by different mechanisms and have 
been shown to inhibit SFV infection (Helenius et al. 1980; Rigg and Schaller 1992; Glomb-
Reinmund and Kielian 1998). When used in BHK and PTH cells (Fig. 33 and 34), these 
drugs could completely abolish SFV infection in both cell types.  
  
 
Figure 33: SFV infection of BHK cells is dependent on low endosomal pH. Cells were preincubated 
with 100 nM Bafilomycin A1, 20 mM NH4Cl or 10 µM Monensin (30 min, 37°C) and subsequently infected (MOI 
10). Immunostainig for newly produced SFV E1/E2-protein (red) and nuclei (blue) was performed 5 h p.i. a) 
untreated cells without inhibitor, b) Bafilomycin A1-treated cells, c) NH4Cl-treated cells, d) Monensin-treated 
cells, e) uninfected control. f) Three randomly chosen fields were analyzed for the amount of E1/E2 positive 
cells. Data are expressed as percentage ± SD of E1/E2 positive cells in untreated cells. Scale bars: 50µm. 
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Figure 34: SFV infection of PTH is dependent on low endosomal pH. Prior infection (MOI 1000) the 
cells were pretreated with 100 nM Bafilomycin A1, 20 mM NH4Cl or 10 µM Monensin (30 min, 37°C), fixed  8 h 
p.i. and stained for newly produced SFV E1/E2-protein (red) and nuclei (blue). a) untreated cells without 
inhibitor, b) Bafilomycin A1-treated cells, c) NH4Cl-treated cells, d) Monensin-treated cells, e) uninfected 
control. f) Three randomly chosen fields were analyzed for the amount of E1/E2 positive cells. Data are 
expressed as percentage ± SD of E1/E2 positive cells in untreated cells. Scale bars: 50µm. 
 
 
 
 
 
 
 
Treatment with BafA1 or NH4Cl had no effect on HBsAg uptake (Fig. 35) and HBV infection 
(Fig. 36). Interestingly, infection in the presence of NH4Cl showed an increase in secreted 
HBsAg signal 14 days after infection, suggesting an increased infection rate (b). There was 
also no sign of inhibition of infection when Monensin was used (c and d).    
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Figure 35: HBsAg uptake in presence of lysosomotropic 
agents. PTH were preincubated with 8ng HBsAg (4°C, 2 h) before 
100 nM Bafilomycin A1 or 20 mM NH4Cl was added and the cells 
were shifted to 37°C for 2 h. The cells were stained for SHBs (green) 
and nuclei (blue). a) untreated cells without inhibitor, b) 
Bafilomycin A1-treated cells, c) NH4Cl-treated cells , d) negative 
control without HBsAg. Confocal images show a cut view through z-
stack- images of single cells. 
 
 
 
 
 
 
 
 
 
Figure 36: HBV infection of PTH in presence of lysosomotropic agents. The cells were preincubated 
with Bafilomycin A1 (100 nM), NH4Cl (20 mM) or Monensin (10 µM) for 30 min at 37°C and afterwards infected 
with purified plasma-derived HBV virions (2.00E+07 GE). cccDNA-formation of incoming viral particles was 
determined 20 h p.i. by PCR and detected by gel electrophoresis (a). Newly secreted HBsAg was measured 14 
days p.i. (b). Data in b) and d) are means of triplicate experiments ± SD. 
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4.6 Cytoskeleton 
The cytoskeleton is a network made from filamentous proteins such as actin, tubulin and 
intermediate filaments in the cytoplasm of eukaryotic as well as prokaryotic cells 
(Graumann 2007; Pollard and Cooper 2009). It stabilizes the cell and its intracellular 
organelles and is also responsible for the motility of organelles and the cell itself (Doherty 
and McMahon 2008). Fig. 37 shows the cytoskeletal organization in PTH after 
immunostaining of actin and microtubules: 
 
 
Figure 37: Cytoskeletal organization in PTH. Cells were fixed three days after isolation and stained for 
actin (using Alexa Fluor®647 phalloidin; red) and microtubules (using an anti-tubulin antibody; green). Nuclei 
(blue). Scale bar: 50 µm. 
 
There are different types of actin-structures in the cell ranging from the dense cortex at the 
cytoplasmic site of the plasma membrane, actin-rich formations associated with endocytic 
or phagocytic structures, long filaments in filopodia etc. (Doherty and McMahon 2008). 
Actin is required for various types of endocytic processes (Mercer et al. 2010) in which both 
actin depolymerization and polymerization have been proposed to allow vesicle formation 
(Doherty and McMahon 2008). Intracellular microtubule-based transport, generally used 
for routing cellular cargoes, such as endosomes or secretory vesicles, is commonly exploited 
by viruses to reach their replication site inside the host cell (Greber and Way 2006). 
Whether functioning actin filaments and microtubules are needed for cytoplasmic 
trafficking of SFV, SV40 and HBV upon entry should be determined by using the following 
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pharmacological inhibitors: Jas which stabilizes F-actin or CytoD which causes actin 
depolymerization (Burckhardt and Greber 2009) and Nocodazole (Noco) which 
depolymerizes microtubules (Vasquez et al. 1997).  
Preincubation with the above-mentioned cytoskeleton disrupting agents had no effect on 
SFV infection in BHK cells and PTH since there was virtually no difference in the number of 
infected cells compared to the untreated control (Fig. 38 and 39). The relatively high 
inhibitor concentrations (see also Figs. 43, 45, 47) were tolerated by PTH and also by the 
BHK cells with the exception of Jas (Fig. 38b). These cells showed a shrinked morphology 
but were nevertheless clearly infected. 
 
 
Figure 38: Impact of cytoskeleton destroying agents on SFV infection of BHK. Prior infection (MOI 
10) the cells were left untreated (a) or preincubated with 1 µM Jasplakinolide (b), 50 µM Cytochalasin D (c) or 
50 µM Nocodazole (d) for 30 min at 37°C. The cells were fixed 5 h p.i. and newly synthesized SFV E1/E2-protein 
(red) and nuclei (blue) were stained. e) uninfected control. f) Three randomly chosen fields were analyzed for 
the amount of E1/E2 positive cells. Data are expressed as percentage ± SD of E1/E2 positive cells in untreated 
cells. Scale bars: 50µm. 
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Figure 39: SFV infection of PTH in presence of actin-and microtubule disrupting agents. Cells 
were were left untreated (a) or preincubated with 1 µM Jasplakinolide (b), 50 µM Cytochalasin D (c) or 50 µM 
Nocodazole (d) for 30 min at 37°C, subsequently infected (MOI 1000), fixed 8 h p.i. and stained for newly 
produced SFV E1/E2-protein (red) and nuclei (blue). e) uninfected control. f) Three randomly chosen fields 
were analyzed for the amount of E1/E2 positive cells. Data are expressed as percentage ± SD of E1/E2 positive 
cells in untreated cells. Scale bars: 50µm. 
 
 
 
 
 
Next, the effect of treatment of cells with Jas, CytoD and Noco on SV40 infection was 
studied. SV40 is dependent on caveolae-mediated endocytosis and microtubule-based 
transport (Kartenbeck, Stukenbrok et al. 1989). SV40 infection was completely abolished in 
Noco-treated cells (Fig. 40d) but was unaffected when the actin-stabilizing drug Jas was 
used (b). However, an approx. twofold reduction in infection was observed in the CytoD-
treated cells which probably results from the fact that the cells showed already signs of 
apoptosis (c).   
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Figure 40: Effect of cytoskeleton disrupting agents on SV40 infection of CV-1 cells. Prior infection 
with 3.00E+03 GE the cells were preincubated with 1 µM Jasplakinolide (b), 50 µM Cytochalasin D (c) or 50 µM 
Nocodazole (d) for 30 min at 37°C. Immunostaining for early large T-antigen expression (red) and nuclei (blue) 
was performed 10 h p.i. e) uninfected control. f) Five randomly chosen fields were analyzed for the amount of 
cells expressing large T-antigen. Data were expressed as percentage ± SD of T-antigen expression in untreated 
cells. Scale bars: 50µm. 
 
 
 
 
Jas, CytoD and Noco were also used to test a possible requirement of a functional 
cytoskeleton for HBsAg uptake and HBV infection, respectively. The inhibitors were utilized 
in the same concentrations as in the previous experiments. Fig. 41 demonstrates that the 
uptake of HBsAg into PTH was reduced by all chemicals to a certain degree. Similarly, all 
drugs affected HBV infection (Fig. 42) which showed a decrease in secreted HBsAg levels to 
30-50% (b) and only very limited cccDNA formation from incoming viral particles after     
20 h of infection (a). 
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Figure 41: Impact of Jasplakinolide, Cytochalasin D and Nocodazole on HBsAg uptake. After 
preincubation with 8ng HBsAg (4°C,  2 h), the chemicals were added to the cells which were then shifted to 37°C 
for 2 h. Staining for SHBs (green) and nuclei (blue) was performed 2 h later. a) untreated cells without inhibitor, 
b) Jasplakinolide (1 µM), c) Cytochalasin D (50 µM), d) Nocodazole (50 µM), e) negative control without HBsAg. 
Confocal images show a cut view through z-stack-images of single cells. 
 
 
 
 
 
 
 
 
Figure 42: HBV infection of PTH in presence of 
cytoskeleton altering agents. The cells were 
preincubated with 1 µM Jasplakinolide, 50 µM 
Cytochalasin D or 50 µM Nocodazole (30 min at 37°C) and 
subsequently infected with purified plasma-derived HBV 
(5,48E+09 GE). cccDNA-formation of incoming viral 
particles was determined 20 h p.i. by PCR and detected by 
gel electrophoresis (a). Newly secreted HBsAg was 
measured 14 days p.i. (b). Data in b) are means of 
triplicate experiments ± SD. 
 
 
 
 
 -Results-                                                 64 
To analyze whether this inhibitory effect of these agents also takes place with lower 
concentrations, PTH were incubated with serial dilutions of Jas, CytoD and Noco and either 
fixed for immunostaining or infected with purified HBV virions. Fig. 43a-e illustrates the 
appearance of PTH after a 4 h-treatment with Jas. The actin staining dissolves with 
increasing drug concentration which can be explained by the fact that Jas occupies the 
phalloidin binding sites on actin. Hence, the more drug is used the less dye can bind to 
actin. Preincubation of PTH with different Jas concentrations prior HBV infection lead to a 
dose-dependent reduction of up to approx. 75% (Fig. 44). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43: Effect of Jasplakinolide on the cytoskeleton of PTH. The cells were either left untreated (a) 
or incubated with different concentrations of Jasplakinolide: b) 0.25 µM, c) 0.5 µM, d) 1 µM, e) 2 µM for 4 h. 
The cells were washed, fixed and subsequently stained for actin (red), microtubules (green) and nuclei (blue). 
Representative images are shown. Scale bars: a) 25 µm, b-e) 10 µm. 
 
 
 
 
Figure 44: Effect of Jasplakinolide on HBV 
infection of PTH. PTH were incubated with the 
indicated Jasplakinolide concentrations (30 min, 
37°C) and subsequently infected with purified 
plasma-derived HBV virions (5,48E+09 GE). 
Newly secreted HBsAg was measured 14 days p.i. 
Data represent the average of three independent 
experiments ± SD. 
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The impact of CytoD on the cytoskeletal architecture of PTH is depicted in Fig. 45. Since 
this inhibitor blocks actin polymerization by binding to the growing plus-end of the 
filaments whereas the minus-end is constantly degraded, only knob-like structures are left 
over and can be stained by phalloidin (b-e). Regarding HBV infection, 5-25 µM had a 
slightly enhancing effect whereas higher concentrations of 50 and 100 µM inhibited 
infection down to 25% of control infection (Fig. 46).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45: Impact of Cytochalasin D on the cytoskeleton of PTH. The cells were either left untreated 
(a) or incubated for 4 h with different concentrations of Cytochalasin D: b) 5 µM, c) 10 µM, d) 25 µM, e) 50 µM. 
The cells were washed, fixed and subsequently stained for actin (red), microtubules (green) and nuclei (blue). 
Representative images are shown. Scale bars: a) 25 µm, b-e) 10 µm. 
 
 
 
 
 
 
Figure 46: Impact of Cytochalasin D on 
HBV infection of PTH. PTH were incubated 
with the indicated Cytochalasin D concentrations 
(30 min, 37°C) and subsequently infected with 
purified plasma-derived HBV virions (5,48E+09 
GE). Newly secreted HBsAg was measured 14 
days p.i. Data are means of triplicate experiments 
± SD.  
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The microtubule pattern in untreated PTH shows a filamentous staining that is occasionally 
concentrated near the nuclei presumably presenting the microtubule-organizing center 
(MTOC) (Fig. 47a, arrowheads). Treatment with Noco leads to a disruption of the 
microtubule network with apparently twisted tubules (b-e). 
Furthermore, a dose-dependent inhibition of HBV was observed in the Nocodazole-
approaches (Fig. 48). 
 
 
 
Figure 47: Impact of Nocodazole on the cytoskeleton of PTH. The cells were either left untreated (a) or 
incubated for with different concentrations of Nocodazole: b) 5 µM, c) 10 µM, d) 25 µM, e) 50 µM. The cells were 
washed, fixed and subsequently stained for actin (red), microtubules (green) and nuclei (blue). Representative 
images are shown. Scale bars: a-c) 25 µm, d+e) 10 µm. 
 
 
 
 
Figure 48: Impact of Nocodazole on HBV 
infection of PTH. PTH were incubated with the 
indicated Nocodazole concentrations (30 min, 
37°C) and subsequently infected with purified 
plasma-derived HBV virions (5,48E+09 GE). 
Newly secreted HBsAg was measured 14 days p.i. 
Data represent the average of three independent 
experiments ± SD.  
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4.7 Retrograde pathway 
Retrograde transport describes the trafficking of endosomes to the biosynthetic/secretory 
compartments, e.g. the Golgi apparatus or the ER, and is important for certain cellular 
functions such as receptor trafficking and cell signaling (Johannes and Popoff 2008). Some 
bacterial toxins use the endosome-to-ER trafficking (Lord and Roberts 1998) and also 
viruses rely on this entry route: SV40 enters its host cells through caveolin-mediated 
endocytosis (Pelkmans et al. 2001). The next step is microtubule-dependent transport to 
the ER (Kartenbeck et al. 1989) from which it  translocates into the cytosol and is thought to 
enter the nucleus via nuclear pore complexes (Schelhaas et al. 2007). The SV40 infection 
process can therefore be blocked by drugs that depolymerize the microtubule-based 
transport (e.g. Noco, see above), BFA affecting GTPase Arf1-activation (Damm et al. 2005), 
inhibitors of proteasomal degradation, e.g. MG-132, and ER Ca2+-homeostasis, e.g. 
Thapsigargin (Schelhaas et al. 2007) which could be reproduced in this work (Fig. 49).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49: SV40 infection in CV-1 cells relies on functional GTPase Arf1-activity and ER-
associated processes. Cells were left untreated (a) or preincubated with 0.1 µg/ml Brefeldin A (b), 1 µM 
Thapsigargin (c) and 20 µM MG-132 (d) for 30 min at 37°C and subsequently infected with 3.00E+03 GE. 
Immunostaining for early large T-antigen expression (red) and nuclei (blue) was performed 10 h p.i. e) 
uninfected control. f) Five randomly chosen fields were analyzed for the amount of cells expressing large T-
antigen. Data were expressed as percentage ± SD of T-antigen expression in untreated cells. Scale bars: 50µm. 
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The HBV infection could not be blocked by Dynasore (Fig. 24) and was shown to be 
independent of low endosomal pH (Fig. 36). Additionally, PTH did not show cav-1-
expression (Fig. 27), therefore the entry mechanism might resemble the uptake of SV40 in 
cav-1 deficient cells (see above). Furthermore, the disulfide bond-containing S-domains of 
HBV which are important for infection (Abou-Jaude et al. 2007; Grün-Bernhard 2008) 
perhaps need to be reduced during the entry process. This could take place in the ER and 
therefore resemble the SV40 infection mechanism (see above). To test this, the same 
concentrations of BFA, Thapsigargin and MG-132 as in the SV40-approach were used 
during HBV infection. Inhibition of Arf1-GTPase activation with BFA caused a minor 
reduction in secreted HBsAg-signal (Fig. 50b) but hardly no difference in cccDNA-
formation of incoming viruses was observed (a). Pertubation of ER-associated processes 
using MG-132 or Thapsigargin had no influence on HBV infection (c and d).  
 
 
 
Figure 50: Effect of Brefeldin A and inhibitors of ER-processes on HBV infection of PTH. Prior 
infection with purified plasma-derived HBV virions (5,48E+09 GE) the cells were preincubated with Brefeldin A 
(1 µg/ml), MG-132 (20 µM) or Thapsigargin (1 µM) for 30 min at 37°C. cccDNA-formation of incoming viral 
particles was determined 20 h p.i. by PCR and detected by gel electrophoresis (a+c). Newly secreted HBsAg was 
measured 14 days p.i. (b+d). Data in b) and d) represent two independent experiments ± SD. 
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Table 4 summarizes the previously shown results gained with the different markers and pharmaceutical inhibitors. 
 
 
Table 4: Summarized results 
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4.8 Transfection of PTH 
4.8.1 Lipofection vs. electroporation 
Besides using pharmaceutical inhibitors to study different internalization pathways it is 
possible to target key proteins of particular cellular endocytic pathways by introducing 
dominant-negative (dn) mutant versions of those into the cells. One way to accomplish that 
is transfection of the cells with expression vectors encoding dn-mutant proteins. 
Unfortunately, the transfection of primary cells is challenging since most methods working 
effectively for cell lines in culture fail to yield satisfying results in primary cells. The 
Amaxa®Nucleofector technology (Amaxa) provides a technique designed for primary cells 
and hard-to-transfect cell lines based on the method of electroporation and was compared 
with the lipofection agent FuGene® (Roche). PTH were transfected with low endotoxin 
pmaxGFP-plasmid DNA either two days after isolation (FuGene®; adherent cells) or directly 
after isolation (Amaxa®; suspension cells). Fig. 51 shows representative images of GFP-
expression 48 h post-transfection. In the FuGene®-approach only the smaller epithelial-like 
cells in the space between the hepatocytes showed GFP-expression (a, arrowheads). The 
Amaxa®Nucleofection indeed allowed the transfection of hepatocytes although only very 
few cells showed GFP-expression (b, arrowheads). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51: Transfection of PTH. PTH were transfected with endofree pmaxGFP-plasmid DNA and GFP-
expression was checked after 48 h.  a) FuGene-transfected cells, b) Amaxa-transfected cells. Representative 
pictures are shown. Scale bars: a) 200 µm, b) 50 µm. 
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4.8.2 Transduction by Baculoviruses 
Gene delivery via “BacMam-viruses”, recombinant baculoviruses containing mammalian 
cell-active expression cassettes, was first demonstrated in primary human hepatocytes 
(Kost et al. 2005). Besides insect cells, baculoviruses can also enter mammalian cells and 
direct the expression of e.g. autofluorescent cellular proteins localized to specific 
intracellular compartments. PTH were transduced the day after plating with the 
commercial available “Organelle Lights™” reagent (Invitrogen) encoding for the endosomal 
Rab5-protein fused to RFP (red fluorescent protein). Expression is illustrated in Fig. 52 
showing only few cells expressing the recombinant protein (arrowheads).  
 
 
 
 
 
Figure 52: Transduction of PTH. PTH were 
transduced with Organelle Lights™ BacMam reagent 
(Invitrogen) encoding autofluorescent Rab5-RFP (red 
fluorescent protein) which localizes to endosomes. Rab5-
expression was checked 48h post-transduction (red); 
DAPI-staining of nuclei (blue). Representative picture is 
shown. Scale bar: 50 µm. 
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5. Discussion 
5.1 Binding and uptake of HBsAg 
Attachment of viral particles to cell surface structures of the host is a prerequisite for entry 
and subsequent infection. Previous work has shown that attachment of HBV to susceptible 
hepatocyte cultures and subsequent infection depends on the preS1 domains in the viral 
envelope. Since HBV particles are difficult to obtain in large amounts, many experiments in 
this work were done with preS1-rich HBsAg subviral particles which are comparable to the 
viral envelope. It was shown that these particles bound to PTH with an uneven distribution 
within the hepatocyte population. This heterogeneity supposedly arises from different 
phenotypic states of the cells and their activities and thus determines cell-to-cell variability 
in viral infection (Snijder et al. 2009). On the single-cell level, the confinement of HBsAg in 
distinct patches could argue for an association with specific membrane areas, e.g. raft 
microdomains, and display endocytic spots but this has to be verified in the future. The 
strongest binding was observed at surface protrusions, probably microvilli or lamellipodia. 
A similar staining pattern of HBsAg to PTH was observed by Glebe et al. (2003) using 
conventional immunohistochemistry. Perhaps, these protrusions are enriched in HBV 
receptor(s) that are still not defined. Binding to those structures may also facilitate the entry 
of viruses by inducing retrograde movement on the host membrane towards the cellular 
body (Lehmann et al. 2005). Such actin- and myosin-dependent “surfing” on cellular 
membranes has already been described for different viruses, such as retroviral Murine 
Leukemia Virus (MLV), Ad2, HPV-16 or Vaccinia Virus, and seems particularly important 
for viral transmission (Lehmann et al. 2005; Mercer and Helenius 2008; Schelhaas et al. 
2008; Burckhardt and Greber 2009). Furthermore, PTH supported, in contrast to non-
susceptible cells, the uptake of HBsAg into a not yet known compartment. 
 
5.2 Difficulties in studying endocytic processes 
By now, it is evident that mammalian cells have multiple endocytic pathways with an ever 
increasing number of novel mechanisms being discovered. Furthermore, the knowledge 
about distinct pathways is still growing and the increasing quantity of alternative cofactors, 
adaptors and accessory proteins reveal an unexpected complexity of endocytic mechanisms 
(Marsh and Helenius 2006). However, one has to take great care when comparing results 
that have been made in distinct cell types, since specialized cells may have individual 
pathways occuring in varying proportions in some types but may be completely absent in 
others (Doherty and McMahon 2009). In addition, it is possible that modes of 
immortalization of cell lines or their repeated passage during cultivation could have 
consequences on how endocytic events are configured (Doherty and McMahon 2009; 
Kumari et al. 2010). Also varying conditions in a same cell type, e.g. cell density or 
adhesion, as well as differences in the experimental procedures, can lead to a switch to 
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another uptake route of the same endocytic cargo (Mayor and Pagano 2007; Sandvig et al. 
2008). Finally it should be considered, that not all endocytic mechanisms identified in vitro 
need to reflect the situation in vivo since viruses also adapt to growth conditions in tissue 
culture (Marsh and Helenius 2006).  
 
5.2.1 Methods for the classification of endocytic mechanisms 
Several tools and approaches can be used to classify the different endocytic mechanisms 
and are discussed in the following. Identification of the ultrastructural morphology by EM 
provides the simplest way to define pathways. Until now, four different structures have 
been determined: the electron-dense coat of CCPs, flask-shaped invaginations (i.e. caveolae 
or similar structures containing flotilins), larger vesicles originating from macropinocytic or 
phagocytic uptake and polymorphous tubular structures (Hansen and Nichols 2009). This 
method, however, requires fixed samples. Thus, it is possible that certain structures which 
are sensitive to the fixation procedure, cannot be visualized at all (Doherty and McMahon 
2009). In addition, one cannot be sure that the observed invaginations always represent 
nascent pits and really would have undergone scission from the PM before fixation (Hansen 
and Nichols 2009). Also, tubular structures may appear spherical in a cross section leading 
to misinterpretations (Doherty and McMahon 2009).  
Another classification criterion for defining different endocytic mechanisms can be 
utilization of certain cargoes, such as fluorescently labeled analogues of lipids, labeled or 
clustered GPI-APs, toxins and viruses (Mayor and Pagano 2007). It is noteworthy, that 
although some cargoes enter exclusively by one pathway, most ligands can be taken up by 
different processes depending on the cell type or, in the same cell type, sometimes 
simultaneously (Nichols and Lippincott-Schwartz 2001; Sieczkarski and Whittaker 2002; 
Rust et al. 2004; Mayor and Pagano 2007; Doherty and McMahon 2009). However, those 
internalization pathways do not always lead to a productive infection or toxicity and 
therefore not necessarily reflect the in vivo-situation (Nichols and Lippincott-Schwartz 
2001; Sieczkarski and Whittaker 2002). Furthermore, labeling with fluorescent 
dyes/proteins or clustering into distinct microdomains might alter the internalization route 
(Doherty and McMahon 2009). Finally, also the amount of virions or particles used in the 
experimental setup can affect the uptake pathway.  
In addition to the above-mentioned approaches to classify certain pathways, extensive 
studies have been carried out to examine their sensitivity to certain drugs or to identify their 
dependencies on specific molecular markers, such as certain lipids, proteins and kinases 
(Doherty and McMahon 2009). However, one should keep in mind that some regulatory 
factors, such as GTPases, are true key players that may influence more than one individual 
uptake mechanism (Mayor and Pagano 2007). There are various tools to interfere with 
cellular markers ranging from RNA interference (RNAi) techniques, microinjection, 
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dominant-negative mutant proteins to pharmacological inhibitors (Graessmann and 
Graessmann 1983; Tuschl 2001; Sieczkarski and Whittaker 2002; Doherty and McMahon 
2009). Microinjection is a technique for transferring exogenous material, such as RNA 
molecules, inhibitory antibodies or peptides, into cultured cells. The protein-of-interest is 
then either not produced (upon post-transcriptional silencing by small RNAs) or directly 
inhibited by bound antibodies/peptides and thus not functional. However, this displays a 
rather complex method in which special equipment is needed. Since only individual cells 
are targeted, this method is applicable for analysis on the single-cell level but not for cell-
culture-wide approaches. 
Dominant-negative (dn) mutant variants of cellular proteins provide a specific way to 
analyse their relevance for defined pathways within the cell (Sieczkarski and Whittaker 
2002). The dn-mutant version, when expressed, results in an inhibitory phenotype by 
suppression of the endogenous wild-type protein (Mayor and Pagano 2007). The insertion 
of those mutants is usually accomplished by transfection. Unfortunately, primary cells 
cannot be efficiently transfected by the commonly used protocols (Glebe and Urban 2007). 
Transfection of differentiated PTH failed indeed when the conventional lipofection agent 
FuGene® was used. Only the proliferating non-hepatic cells, with an epithelial-like 
morphology, displayed GFP-expression. Therefore specialized methods were tested in the 
present work. The Nucleofector technology permits transfection of particularly primary 
cells and hard-to-transfect cell lines which divide more slowly or are completely mitotically 
inactive (Gresch et al. 2004). Transfection efficiencies obtained with this technology using 
different primary cells of human origin (hepatocytes were not included) ranged from 30-
60% with varying mortality rates depending on the cell type (Hamm et al. 2002; Gresch et 
al. 2004). Using this method, transfection of PTH was possible, though the efficiency of 
<10% was very low. Also transduction with baculoviruses failed to achieve higher 
efficiencies. Since only one in several thousand HBV particles is infectious in the PTH 
system and not all cells seem to have similar binding capacities, only a portion of about    
10-20% hepatocytes can be infected at all (Glebe et al. 2003). A potential inhibitory effect of 
distinct dn-mutant proteins would probably remain undetected if an infection of non-
transfected cells leads to compensation in measured HBsAg levels. Therefore, these 
methods were considered to be inappropriate for the cell-culture-wide analysis of HBV 
entry into PTH. Furthermore, a general drawback of this method is highlighted by the fact 
that cells, expressing dn-mutant proteins, can completely compensate for the loss of this 
particular route by upregulation of an alternative pathway (Damke et al. 1995). This 
physiological regulation of uptake mechanisms may even induce pathways that are 
nonexistent before (Marsh and Helenius 2006; Doherty and McMahon 2009). 
Another tool for direct probing of endocytic mechanisms in living cells is the use of 
pharmacological/chemical inhibitors (Ivanov 2008). These provide several advantages over 
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previously described methods: The application is very easy since the cell culture medium 
simply has to be replaced by drug-containing medium. Pharmacological inhibitors are 
supposed to equally affect all cells in a population and the effects can be easily titrated. 
Finally, the cells are usually exposed to the drugs over a short period which is thought to 
exclude compensatory uptake mechanisms and reduces the likelihood of delayed side 
effects (Ivanov 2008). However, one has to keep in mind that a distinct marker can 
contribute to various pathways and therefore inhibitory drugs might affect more than one 
pathway (Mayor and Pagano 2007; Sandvig et al. 2008). The current information about 
hepadnaviral entry mainly derived from the DHBV model system in which chemical drugs 
were used to reveal early events of infection (Glebe and Urban 2007). However, one has to 
be aware of the differences between HBV and DHBV and the possibility that various uptake 
strategies might have evolved in the two virus genera (Funk et al. 2007; Glebe and Urban 
2007). To elucidate the entry mechanism of HBV into PTH pharmacological inhibitors were 
used as well. Possible nonspecific effects of the drugs (Ivanov 2008) should be uncovered by 
employing several control viruses and substrates with established uptake routes. 
 
5.3 Endocytosis vs. plasma membrane fusion of HBV 
In this study, a dose-dependent inhibition of HBsAg uptake and HBV infection was 
achieved by increasing hypertonic sucrose concentrations. An explanation for this 
observation might be that high sucrose concentrations were shown to cause dispersion and, 
with time, disappearance of cellular clathrin lattices at the inner leaflet of the PM and were 
therefore thought to impair CME exclusively (Daukas and Zigmond 1985; Heuser and 
Anderson 1989). This is in line with the sucrose-dependent inhibition of SFV infection, 
known to enter via CME, both in BHK and PTH. More recently, it has been postulated that 
extracellular hypertonicity interferes with endocytic processes in general by inducing cell 
shrinkage thereby remodeling the actin cytoskeleton (Ivanov 2008). This could also explain 
the effect that the infection of the second control virus, namely SV40 known to enter via 
caveolae/raft-dependent endocytosis, was also blocked by hypertonic sucrose dose-
dependently. In contrast, hypertonic sucrose treatment did not inhibit SeV infection which 
starts with direct fusion with the PM thus bypassing endocytic uptake. Combining these 
results, it can be postulated for the first time that HBV enters susceptible cells (here: PTH) 
by an endocytic step rather than by direct fusion with the PM. One might argue that this 
displays a special situation in hepatocytes from Tupaias since these animals are not a 
natural host for HBV and therefore the “real” infection pathway in human hepatocytes is 
different. However, similar experiments with the HBV-susceptible human hepatoma cell 
line HepaRG and identical viral HBV inocula have led to comparable results (König 2010), 
indicating that the postulated HBV entry mechanism by endocytosis is similar for human 
and Tupaia hepatocytes. Since infection experiments with the HepaRG cell line always 
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showed a low infection rate and strong heterogeneity in susceptibility (due to a difficult re-
differentiation process in cell culture necessary for susceptibility; König 2010; Gripon et al. 
2002), all HBV infection experiments in the present study were done with PTH. Due to the 
lack of a suitable HBV-infection model, Köck et al. used the related duck hepatitis B virus 
(DHBV) and primary duck hepatocytes (PDH) to study DHBV uptake and infection. By 
inducing energy depletion of the cells, they observed prevention of DHBV uptake and 
concluded that DHBV enters its host cells by endocytosis (Köck et al. 1996).  
Concerns that the inhibition of HBV infectivity by sucrose may be caused by an altered 
interaction of the viral lipids with the PM can be excluded since the uptake of the non-
enveloped SV40 was affected to a similar extent as the internalization of enveloped viruses 
(SFV). Moreover, the used HBV viral- and subviral particle-fractions have been purified by 
a sucrose gradient and the remaining sucrose amounts (43% for the virion fraction) neither 
altered particle integrity nor infectivity (Glebe et al. 2003; Glebe et al. 2005). This argues 
for an impairement of endocytotic events by sucrose rather than effects on the viruses 
themselves.  
After showing that an endocytic step is necessary for HBV entry, the next task was to 
identify the cellular endocytic pathway(s) which mediate(s) HBV entry. This was done with 
the use of specific chemical inhibitors of key enzymes or proteins of the respective 
pathways.    
 
5.4 Dynamin-dependent endocytosis 
5.4.1 Clathrin-mediated endocytosis 
CME is an extremely important endocytic mechanism and the most commonly used route 
for viruses to enter their host cells (Marsh and Helenius 2006). CME is a constitutive and 
fast pathway that delivers its cargo within a few minutes from the surface to intracellular 
organelles. SFV was the first virus shown taking CME as productive infectious route and 
many other viruses, such as VSV, Ad2 and 5, as well as Influenza Virus followed (Helenius 
et al. 1980; Cureton et al. 2009; Mercer et al. 2010). Regarding the just mentioned 
examples, the versatile nature of CME becomes apparent: not only small or medium-sized 
viruses, like SFV (60-70 nm) and Influenza (90-120 nm) use this pathway, but also larger 
particles, such as the bullet-shaped VSV (180 x 70 nm) and even bacteria (Cossart and Veiga 
2008). 
Former HBV infection studies in PTH showed that chlorpromazine, which prevents the 
assembly of CCPs at the PM (Wang et al. 1993), did not block HBV infection (Grün-
Bernhard 2008). Since this inhibitor is considered to have unspecific effects on other 
intracellular enzymes (Sieczkarski and Whittaker 2002; Ivanov 2008) utilization of 
Dynasore, a specific inhibitor of dynamin (Macia et al. 2006), was preferred. Given the fact 
that CME strictly relies on functional dynamin, preincubation with the drug Dynasore 
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completely abolished CME-dependent SFV infection in both cell types, BHK and PTH. As 
expected, direct fusion of SeV with the PM was not impaired, neither in CV-1 cells nor in 
PTH. Preincubation with Dynasore did not affect HBsAg uptake or HBV infection, 
indicating that dynamin-activity is not needed for these processes. Therefore, it is likely that 
HBV does not use CME or any other dynamin-dependent pathway as endocytic route.  
Cooper and Shaul proposed CME to be the uptake mechanism used by recombinant HBV 
core particles in HepG2 and Cos7 cells (Cooper and Shaul 2006). Neither  HepG2 cells nor 
Cos7 cells, an immortalized kidney cell line, are susceptible for HBV infection (Glebe and 
Urban 2007) and free HBV core particles do not occur in the plasma of infected individuals. 
Furthermore, the authors used a huge and unphysiological amount of HBV core particles 
for their studies (Cooper and Shaul 2006). Therefore, those results are not relevant for the 
natural HBV infection process, but represent more likely an example for the utilization of 
CME as a constitutive and efficient uptake mechanism.  
 
5.4.2 Caveolin-mediated endocytosis 
Lipid raft-mediated endocytosis has increasingly been brought in connection with clathrin-
independent entry pathways. These microdomains are rich in sphingolipids and cholesterol 
and are thought to occur in different manifestations (Parton and Richards 2003). One 
subtype of lipid rafts are caveolae which are formed principally by the assembly of 
caveolins, especially cav-1 (Simons and Toomre 2000; Kumari et al. 2010). Cav-1 can form 
higher-ordered oligomers and directly binds membrane cholesterol (Murata et al. 1995), 
therefore caveolae represent structures particularly enriched in this component (Doherty 
and McMahon 2009). Inhibition of this pathway can be achieved by several drugs with 
sterol-binding ones, such as Nystatin or MßCD, being the most effective (Sieczkarski and 
Whittaker 2002). Cholesterol depletion leads to flattening and disassembly of caveolae and 
has been shown to block endocytosis of different caveolin-dependent cargoes (Doherty and 
McMahon 2009; Kumari et al. 2010). Our group is the first to show that HBV infection of 
PTH is not dependent on cholesterol within the cellular PM, since an extraction of 
cholesterol by MßCD (up to 10 mM) did not affect the HBV infection (present work and 
Bremer et al. 2009). In the present study, the caveolae-dependent SV40 infection of CV-1 
cells was completely abolished even at low concentrations (3 mM MßCD). Also, treatment of 
PTH with genistein, a Src-family kinase inhibitor known to block the caveolae-dependent 
entry pathway (Nichols 2003), had no effect on HBV infection (Bremer et al. 2009). 
However, the most important results came from the treatment of the cells with Dynasore, 
inhibiting besides CME also dynamin-dependent caveolae-mediated endocytosis. While 
abrogating SV40 infection as expected, it had no impact on HBV binding, uptake and 
infection. 
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Recently, it was hypothesized that HBV infection of the HepaRG cell line depends on 
caveolin-mediated endocytosis (Macovei et al. 2010). As already mentioned, this human 
hepatoma cell line is permissive for HBV infection only after an unknown differentiation 
process induced by treatment with DMSO and hydrocortisone (Gripon et al. 2002). The 
authors used the HepaRG cell line to stably express dn-mutant variants of cav-1 and 
dynamin-2 to investigate the implication of caveolae in HBV internalization (Macovei et al. 
2010). Unfortunately, it was not convincingly shown that in dn-mutant expressing cells, a 
complete inhibition of HBV infection has taken place. Moreover, treatment of the original 
HepaRG cell line with pharmacological inhibitors, like MßCD or genistein, did also not 
impair infection significantly which is consistent with our previously published data using 
PTH (Bremer et al. 2009). In our hands, cholesterol depletion of re-differentiated HepaRG 
cells with MßCD had also no effect on HBV infection (König 2010). Interestingly, the 
experiments to compare the cav-1 content of PTH with that of other cell types revealed that 
PTH did not express cav-1, which is consistent with other reports stating that hepatocytes 
per se have only few or no caveolae (Fielding and Fielding 2000; Vainio et al. 2002; Ikonen 
et al. 2004; Woundenberg et al. 2010). In contrast, HepaRG cells showed a very strong 
expression of cav-1 particularly in their differentiated and HBV-susceptible state. Since 
overexpression of cav-1 strongly increases the number of caveolae in a given cell type, it 
simultaneously reduces overall membrane fluidity and therefore even inhibits caveolin-
mediated endocytosis (Doherty and McMahon 2009). For that reason, it will be important 
to elucidate the specific function and regulation of caveolar assembly and budding in the 
HepaRG cell line to find out whether HBV uses this pathway as entry portal in that 
particular cell type. In addition, caution is advised since there is always the possibility that 
signaling pathways responsible for controlling caveolar events are somehow misregulated in 
long term cultured cell lines (Hansen and Nichols 2009). 
 
5.5 Dynamin-independent endocytosis 
5.5.1 Phagocytosis 
Phagocytosis occurs mainly in specialized cells of the immune system and beside its 
function of internalizing and destroying opsonised material, this process turned out to be an 
entry portal for certain bacteria (Kinchen and Ravichandran 2008). Interestingly, although 
not commonly used for entry, also large viruses, such as HSV-1 or Mimivirus, exploit this 
pathway (Clement et al. 2006; Ghigo et al. 2008). One reason for this may simply be their 
size which probably makes it more difficult to use standard-sized endocytic vesicles 
(Schelhaas 2010). In contrast to macropinocytosis, phagocytosis depends on specific ligand-
receptor interactions and could therefore offer a cell type-specific entry pathway. Since HBV 
infection is dependent on the interaction of its preS1-domain with a yet uncharacterized 
receptor (Glebe and Urban 2007) the possibility of a receptor-induced phagocytic entry was 
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examined using HBsAg and fluorescently labeled bacteria as a marker for phagocytosis. The 
bacteria were observed exclusively in smaller non-hepatic cells whereas HBsAg particles 
were found in PTH only. This suggests that PTH are not capable of phagocytosis. Moreover, 
since this mechanism seems to be dependent on dynamin in some cell types (Doherty and 
McMahon 2009) it apparently does not display the endocytic pathway used by HBV. 
 
5.5.2 Macropinocytosis 
In contrast to the above-mentioned processes, macropinocytosis describes a rather 
unspecific endocytic mechanism used for internalization of large amounts of extracellular 
compounds, such as fluids and solutes, and does not rely on a defined ligand-receptor-
binding (Doherty and McMahon 2009). However, macropinocytosis can be transiently 
induced by external stimulation, some pathogens themselves trigger this process by binding 
to cell surface proteins which has been shown for Ad2 (Meier et al. 2002). Experiments in 
the PTH system showed that, in contrast to the results obtained with Ad2, prebinding of 
HBV did not lead to transient stimulation of fluid phase uptake. Neither Dynasore nor 
Blebbistatin had an effect on the uptake of HRP, a known fluid phase marker (Haigler et al. 
1979). This shows, that dynamin, which has been reported to be required for this process in 
some systems (Mercer and Helenius 2009), is not needed for macropinocytic endocytosis in 
PTH. Induction of large membrane extrusions, so-called blebs, during macropinocytic entry 
of Vaccinia Virus (Mercer and Helenius 2008) as well as virus “surfing” along filopodia 
(Lehmann et al. 2005), is reduced upon treatment with Blebbistatin (Straight et al. 2003; 
Mercer and Helenius 2008). Blebbistatin is a specific inhibitor of class II myosins (Straight 
et al. 2003) which are anchored in the actin mesh at the cell body/cortex and act as 
molecular motors fulfilling essential functions, such as muscle contraction, cytokinesis, 
neurite outgrow and retraction, in most eukaryotic cells (Kovacs et al. 2004; Burckhardt 
and Greber 2009). Inhibition of myosin II by Blebbistatin prevents retrograde actin flow, 
virus drifts and infection (Burckhardt and Greber 2009). Bleb formation in PTH seems 
either not to exist or does not contribute to macropinocytosis, since no inhibition of HRP 
internalization in the presence of Blebbistatin was observed. In contrast to that, impairment 
of the cytoskeleton function by Jas or CytoD, brought a reduction in HRP uptake reflecting 
the expectation that actin modulation is definetely required for macropinocytosis regardless 
in which cell types (Doherty and McMahon 2009). Further cellular factors required for 
macropinocytosis are numerous, interconnected with other endocytic mechanisms and 
depend, to a certain extent, on the cell type (Sieczkarski and Whittaker 2002; Doherty and 
McMahon 2009; Mercer et al. 2010). However, Na+/H+exchangers have been implicated to 
be crucial for this mechanism which distinguishes it from other types of endocytosis 
(Koivusalo et al. 2010). The exact mechanism of action of this drug remains largely 
unknown, but recently it has been postulated that amilorides inhibit the macropinocytic 
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process by lowering submembranous pH and prevent signaling of distinct GTPases 
(Koivusalo et al. 2010). Specific inhibition of macropinocytosis using EIPA, a blocker of 
Na+/H+exchangers (Ghigo 2010), reduced the uptake of the fluid phase marker HRP, 
confirming the susceptibility of this process towards this drug. However, it had no impact 
on the internalization of HBsAg and HBV infection. Based on the observations that binding 
of HBV did not stimulate macropinocytic activity of PTH and neither HBsAg internalization 
nor HBV infection was blocked by EIPA, one can postulate that HBV does not enter PTH via 
macropinocytosis. 
 
5.5.3 CLIC/GEEC, flotilin and TEM pathways 
Besides macropinocytosis, another mechanism for fluid phase uptake has been discovered a 
few years ago: the CLIC/GEEC pathway describes, contrary to macropinocytosis, a 
constitutive route which is dependent on the small GTPase cdc42 (Sabharanjak et al. 2002). 
Cargo delivery through this route does not occur in classical small spherical vesicles but 
involves larger, polymorphous structures appearing almost tubular in ultrastructural 
analysis. CLIC/GEEC membranes can either fuse with early endosomes or traffic directly to 
compartments such as the Golgi (Doherty and Lundmark 2009) possibly providing a direct 
route to perinuclear regions. Cells may have evolved this mechanism especially for the 
efficient uptake of large amounts of cargo and/or fluid within one single budding event 
(Mayor and Pagano 2001; Polishchuk et al. 2009). Treatment with Brefeldin A (BFA), a 
fungal metabolite known to affect Arf1-activation, lead to an enhanced fluid phase uptake of 
HRP which has been already described (Kumari and Mayor 2008). In contrast to that, HBV 
infection was slightly reduced when this drug was used, suggesting this pathway to be 
irrelevant for HBV entry. More detailed information about the molecular machineries 
involved in this endocytic event is still lacking, but it has been suggested that it is sensitive 
to cholesterol depletion and is, at least in some cells, dynamin-dependent (Mayor and 
Pagano 2007; Hansen and Nichols 2009). If this also proves true for PTH, it would 
ultimately exclude this pathway for HBV uptake, since neither MßCD (see above and 
Bremer et al. 2009) nor Dynasore (see above) have an impact on infection. More data on 
the roles of different cellular marker proteins will resolve this issue in the future. 
Another specific clathrin-independent endocytic pathway is suggested to rely on flotilins 
which assemble into microdomains similar to those formed by caveolins (Hansen and 
Nichols 2009). The uptake of proteoglycan-binding ligands has been reported to be flotilin-
dependent (Payne et al. 2007) and hence could be a possible route for HBV which binds to 
heparan-sulfate proteoglycans (HSPGs) as described by our group (Leistner et al. 2008) 
and others (Schulze et al. 2007). However, Payne et al. found this pathway to be dependent 
on dynamin and, based on their observations, they finally suggested that this mechanism 
may be used by proteoglycan-binding ligands that lack secondary receptors (Payne et al. 
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2007). This would exclude HBV, whose infection is not dependent on dynamin action  
(present work) but on (a) specific receptor(s) (Glebe and Urban 2007).  
Whether the recently discovered invasion mechanism for HPV-16, which is clathrin-, 
caveolin-, flotilin-, lipid raft-, dynamin-independent and involves tetraspanin-enriched 
microdomains (TEMs) (Spoden et al. 2008; Mercer et al. 2010) could also come into 
question for HBV entry needs to be tested in the future. 
 
5.6 pH-dependence of HBV infection 
The pH regulation within endosomal compartments is mainly modulated by v-ATPases, 
which are ATP-driven multisubunit proton pumps, ubiquitously expressed in all eukaryotic 
cells (Jefferies et al. 2008). The establishment of a low pH within cellular organelles can be 
prevented by several lysosomotropic agents, such as BafA1, which specifically inhibits the  
v-ATPases, the ionophore Monensin or the weak base NH4Cl (Bowman et al. 1988; Glomb-
Reinmund and Kielian 1998). These drugs raise the pH of endocytic organelles and 
prevented the establishment of the SFV infection in BHK cells and PTH in the present work, 
but did not impair HBsAg uptake or cccDNA formation in the PTH system. The amount of 
newly secreted particles after 14 days was also not reduced, but rather showed increased 
HBsAg amounts. The reason for this enhanced infection or production can currently not be 
explained, however, a similar phenomenon was observed in HepaRG cells (König 2010) and 
has also been described in the DHBV system (Rigg and Schaller 1992). Other studies that 
investigated the requirement of acidification during DHBV infection came to contradictory 
results: Offensperger et al. observed inhibition of infection by using NH4Cl (Offensberger et 
al. 1991). Since the authors used long incubation times of up to several days, it is likely that 
not only the initiation of infection, but also late steps of the viral life cycle were affected, 
which has already been reported (Carillo et al. 1984; Cassell et al. 1984; Marsh and Helenius 
1989). In other studies where the NH4Cl-treatment lasted only a few hours, no inhibition 
was observed (Rigg and Schaller 1992; Funk et al. 2006). Although the results obtained with 
NH4Cl indicated that a low pH is indispensable for the establishment of a productive DHBV 
infection, further experiments showed, that virions are transported from early to late 
endosomes and can thereby be blocked by BafA1 (Chojnacki et al. 2005). Funk et al. 
observed the same in PDH and could partially rescue the inhibited phenotype with the 
ionophore Monensin (Funk et al. 2006). BafA1 not only destroys the proton gradient 
generated by the v-ATPases but also the formation of ion motive force across the endosomal 
membrane (Sun-Wada and Wada 2010) which can be partially overcome by the presence of 
Monensin (Malecki et al. 2002). Therefore, Funk et al. concluded that the endosomal 
transmembrane potential generated by the v-ATPases is at least partially necessary for 
DHBV infection (Funk et al. 2006). In contrast to that, HBV infection of PTH (present 
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work) as well as HepaRG cells (König 2010; Glebe and Urban 2007) is not influenced by 
BafA1, indicating, that HBV and DHBV might use different endocytic pathways. 
 
5.7 Role of the cytoskeleton for HBV infection 
Actin polymerization is certainly required for some CME (Doherty and McMahon 2008) 
noting, for example the internalization of VSV (Cureton et al. 2009). In contrast to that, the 
uptake of SFV, known to be taken up via CME, was shown to be unaffected by drugs that 
interfere with the actin cytoskeleton in BHK cells and PTH in the present study. This 
suggests that the decision whether actin provides assistance or not, may in part depend on 
the cargo (here, e.g. its size). Pelkmans et al. showed that the actin-stabilizing drug Jas 
reduced SV40 internalization into CV-1 suspension cells and also blocked infection 
(Pelkmans et al. 2002). However, although Jas is thought to stabilize actin, including the 
submembranous filaments at the PM, some virus-containing vesicles were endocytosed in 
the presence of Jas and remained just below the PM (Pelkmans et al. 2002). In the present 
work, no inhibition of SV40 infection was observed using the same cell line (adherent cells). 
Since actin disrupting drugs were found to have variable effects in a distinct cell type under 
different conditions (Fujimoto et al. 2000), given in the present case (with respect to the 
state of the cells, inhibitor concentrations, incubation period and medium) might explain 
the conflicting results.  
Treatment of PTH with relatively high concentrations of Jas and CytoD, which has led to 
actin disassembly, reduced HBsAg uptake as well as HBV infection by 50-60% rather than 
blocking it completely. This seems to be a specific feature of those kind of actin-targeting 
drugs (Smythe and Ayscough 2006). However, the importance of actin could depend on the 
physiological state in which the cells find themselves: when cells exhibit abundant filopodia, 
e.g. CytoD has greater inhibitory effects on viral infection (Lehmann et al. 2005). This could 
mean that hepatocytes which possess increased amounts of F-actin-rich microvilli on their 
surface are more drug-sensitive, whereas cells without those special membrane structures 
are still able to internalize the virus. Funk et al. argued that the actin cytoskeleton is 
completely dispensable for a productive DHBV infection of PDH (Funk et al. 2004). 
However, the CytoD concentration used in their study (20 µM) was noneffective on HBV 
infection in the present work as well; only higher concentrations lead to a reduced HBsAg 
signal after 14 days and a lower cccDNA content respectively.  
Intracellular trafficking of HBV capsids and incoming DHBV particles was shown to be 
dependent on active microtubule (MT)-based transport since MT-disruption with Noco 
prevented capsid transfer towards the nucleus and also DHBV infection (Funk et al. 2004; 
Rabe et al. 2006). However, the inhibition of DHBV infection in PDH was strong but not 
complete (Funk et al. 2004) which was also observed for HBV infection in the present work. 
This is perhaps due to the fact that not all MTs are completely inactivated by the drug and a 
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few particles are able to reach the nucleus despite the presence of the drug. Furthermore, it 
has been reported that the different membrane sides of polarized cells are not equally 
affected by treatment with drugs that interfere with the cytoskeleton (Doherty and 
McMahon 2008) therefore, the internalization could take place at drug-insensitive spots. 
An alternative explanation could be that in PTH probably MT independent transport 
mechanisms exist, e.g. polymorphous structures similar to those observed in the 
CLIC/GEEC pathway (see chapter 5.5.3) that may provide a direct route to the perinuclear 
region. However, this needs to be tested in the future.  
 
5.8 Retrograde pathway involved in viral uptake 
The retrograde transport pathway, i.e. the endosomal trafficking to the Golgi or ER, is a 
specialized route taken by some surface glycoproteins and is also hijacked by certain 
pathogens or pathogenic products (Johannes and Popoff 2008; Pfeffer 2009). Also, in 
trafficking of SV40 from the PM to the ER this route is crucial for its infectivity (Schelhaas 
et al. 2007). SV40 enters cells via caveolin-or raft-mediated endocytosis which delivers the 
virus into the pH-neutral caveosomes (Pelkmans et al. 2001; Damm et al. 2005). From 
there, SV40 moves along microtubules to the ER (Kartenbeck et al. 1989). Afterwards, the 
virus benefits from the protein folding and quality control factors present in the ER, which 
support initial uncoating, i.e. disulfide bond shuffling within the capsid (Schelhaas et al. 
2007). As demonstrated in the present work, HBV does not rely on dynamin action for 
endocytic uptake and does not need a low pH within endosomal compartments for 
infection. Furthermore, the HBV S-domain contains 8 Cysteine residues, forming inter- and 
intramolecular disulfide bonds within the antigenic loop that are important during the entry 
of the virus (Abou-Jaoude et al. 2007; Grün-Bernhard 2008). Those disulfide bonds are 
essential for infection and possibly have to be reduced during this process so that the core 
particles can be released. This could possibly take place in the ER and show similarities to 
the infection mechanism of SV40. Therefore, the sensitivity of HBV infection towards 
certain drugs, interfering with the SV40 infection of CV-1 cells, was tested. SV40 infection 
was completely abolished when BFA was present (Richards et al. 2002; Damm et al. 2005). 
The inhibitory potential of the drug is based on its effects on Arf1, which belongs to a family 
of regulatory GTPases important for membrane traffic at the ER/Golgi (Richards et al. 
2002; Damm et al. 2005; Kahn 2009). In contrast to that, HBV infection was only slightly 
reduced. The reason for this could be, that BFA has several effects on different membrane 
sides of polarized cells (Klausner et al. 1992) and internalization of HBV at multiple sides, if 
occuring at all, would therefore be differentially impaired. Moreover, the effects of Arf-
family members may be, at least in some instances, cell type specific (Mayor and Pagano 
2007). Therefore, further work needs to be done to characterize the Arf-function in PTH.  
 -Discussion-                                                    84 
In order to infect its host cells, SV40 exploits the ERAD (ER-associated protein 
degradation)-machinery that is normally used to eliminate misfolded or unassembled 
proteins by proteasomal degradation (Meusser et al. 2005; Schelhaas et al. 2007). 
Furthermore, the final dissociation of SV40 capsids seem to occur in the cytosol and relies 
on the Ca2+-gradient present during ER-release (Schelhaas et al. 2007). Pertubation of these 
processes by MG-132, which inhibits proteasomal degradation or Thapsigargin, an inhibitor 
of the ubiquitous ER Ca2+-ATPases (Treiman et al. 1998), impairs the ER-escape of SV40 
and blocks infection (Schelhaas et al. 2007). However, neither of those drugs had any effect 
on HBV infection which indicates that it does not rely on this specialized mechanism for 
initiation of infection. Since the ER redox system contains many different enzymes which 
can assist other viruses during their infection (Burckhardt and Greber 2008) it is 
nevertheless possible that HBV may use a similar entry pathway perhaps by engaging other 
isomerases or chaperones. 
 
5.9 Future issues 
With the Tupaia hepatocyte in vitro model system, it will be possible to characterize further 
viral and cellular interactions important for elucidation of the HBV entry mechanism. 
Several approaches, ranging from EM, single virus particle tracking via confocal microscopy 
to RNAi screens etc., will allow a better understanding of the behavior of HBV during entry 
and possibly uncover definite requirements, such as the high-specific receptor(s) and 
perhaps other accessory proteins and distinct lipid compositions that might play a role in 
the early events of infection. Identification of the molecular machineries needed may also 
lead to development of inhibitors that specifically target key proteins or enzymes of the 
HBV entry process and thereby specifically inhibit infection. HBV is a highly variable DNA 
virus especially under immunity or antiviral therapy, e.g. due to treatment with reverse 
transcriptase inhibitors, resulting in escape mutants and drug resistance (Glebe and Urban 
2007). The emergence of such mutants would be unlikely if entry inhibitors that target 
conserved intermediates of the process (e.g. receptor structures), were used, since 
mutations within the essential preS1-region result in reduction or loss of infectivity. 
Myrcludex B, an acylated HBV preS1-derived lipopeptide, is such an inhibitor: It was shown 
to block virus entry in vitro and in vivo and possibly represents a novel antiviral approach 
of acute and chronic hepatitis B, similar to the HIV-peptide entry-inhibitor 
Fuzeon/Enfuvirtide (Kilby and Eron 2003; Glebe et al. 2005; Gripon et al. 2005; Petersen 
et al. 2008). Potential application areas of this and future viral entry blockers are: post 
exposure prophylaxis (e.g. after needle stick injuries), prophylaxis of re-infection in liver 
transplanted HBV-positive patients and perhaps also during treatment of chronic HBV 
infections (Glebe and Urban 2007).  
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